CN103403025A

CN103403025A - Monovalent antigen binding proteins

Info

Publication number: CN103403025A
Application number: CN2012800108091A
Authority: CN
Inventors: B·柏森迈尔; H·克腾伯格; C·克莱因; K-P·昆克尔; J·T·雷古拉; W·舍费尔; M·施威格; C·苏斯特曼
Original assignee: F Hoffmann La Roche AG
Current assignee: F Hoffmann La Roche AG
Priority date: 2011-02-28
Filing date: 2012-02-24
Publication date: 2013-11-20
Anticipated expiration: 2032-02-24
Also published as: US20180037633A1; US10611825B2; EP2681240B1; EP2681240A1; JP5768147B2; CN103403025B; WO2012116927A1; MX2013009781A; AR085403A1; JP2014509199A; BR112013020338A2; US20120237507A1; KR20130135896A; RU2013141078A; MX342034B; CA2824824A1; KR101572338B1

Abstract

The present invention relates to monovalent antigen binding proteins with a CH1-CL domain exchange, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Description

Monovalent antigen binding protein

The present invention relates to have the monovalent antigen binding protein of CH1-CL Domain swapping, its production method, contain the pharmaceutical composition of described antibody, and uses thereof.

Background of invention

In nearly 20 years, developed and assessed multiple monospecific or polyspecific, (see for example Holliger, P., wait the people to the engineered antibody derivative of unit price or multivalence, Nature Biotech23 (2005) 1126-1136; Fischer, N., and L é ger, O., Pathobiology74 (2007) 3-14).

To some antigen c-Met for example, univalent antibody is compared its corresponding bivalent form and is had different performances, for example after antibodies, lacks the antagonism function or the acceptor internalization reduces, and has therefore represented the favourable form that is used for the treatment of purposes.For example WO2005/063816 relates to the monovalent antibody fragments as therapeutical agent.

US2004/0033561 has described the method based on coexpression VH-CH1-CH2-CH3 antibody chain and VL-CL-CH2-CH3 antibody chain generation univalent antibody; But the shortcoming of this method is the homodimer in conjunction with non-activity that forms the VL-CL-CH2-CH3 chain, as in Fig. 2, described.Due to similar molecular weight, be difficult to separate such homodimer by product.

WO2007/048037 also relates to the univalent antibody based on coexpression VH-CH1-CH2-CH3 antibody chain and VL-CL-CH2-CH3 antibody chain, but it has the part that tags that is attached to heavy chain, for being easy to from the homodimer by product purifying heterodimer that is difficult to separate.

WO2009/089004 has described and has used the static steering effect to generate the another kind of possibility of heterodimer univalent antibody.

WO2010/145792 relates to the tetravalence bi-specific antibody, and wherein the minimizing of the mispairing by product of similar weight causes the bi-specific antibody of the expectation of high yield.

Summary of the invention

The present invention comprises monovalent antigen binding protein, and it comprises

A) the modified heavy chain of the antibody of specific binding antigen, wherein the VH structural domain is replaced by the VL structural domain of described antibody; With

B) the modified heavy chain of described antibody, wherein the CH1 structural domain is replaced by the CL structural domain of described antibody.

In one embodiment of the invention, monovalent antigen binding protein according to the present invention is characterised in that

The CH3 structural domain and b of the modified heavy chain of antibody a)) each comfortable interface of CH3 structural domain of modified heavy chain of antibody contact, described interface comprises the original interface between antibody CH3 structural domain;

Wherein change described interface to promote the formation of monovalent antigen binding protein, wherein said change is characterised in that

I) change the CH3 structural domain of a heavy chain,

Make in the original interface of CH3 structural domain of a heavy chain that contacts at the original interface of CH3 structural domain of another heavy chain with in monovalent antigen binding protein,

Amino-acid residue is had the amino-acid residue of larger side chain volume to be replaced, thereby produces projection in the interface of the CH3 of heavy chain structural domain, and described projection can be placed in the Nei De chamber, interface of the CH3 structural domain of another heavy chain

With

Ii) change the CH3 structural domain of another heavy chain,

Make in the original interface of the 2nd CH3 structural domain that contacts at the original interface of a CH3 structural domain with in monovalent antigen binding protein,

Amino-acid residue is had the amino-acid residue of smaller side chain volume to be replaced, thereby produces chamber in the interface of the 2nd CH3 structural domain, in described chamber, can place the projection in the interface of a CH3 structural domain.

In one embodiment of the invention, this monovalent antigen binding protein according to the present invention is characterised in that

Described amino-acid residue with larger side chain volume is selected from arginine (R), phenylalanine (F), tyrosine (Y), tryptophane (W), and described amino-acid residue with smaller side chain volume is selected from L-Ala (A), Serine (S), Threonine (T), α-amino-isovaleric acid (V).

In one embodiment of the invention, according to the feature of this monovalent antigen binding protein of the present invention, also be

By introducing halfcystine (C) two CH3 structural domains of the further change of amino acid as the corresponding position at each CH3 structural domain, make between two CH3 structural domains and can form disulphide bridges.

In one embodiment, monovalent antigen binding protein according to the present invention is characterised in that it is the human IgG isotype.

In one embodiment, monovalent antigen binding protein according to the present invention is characterised in that and comprises

A) modified heavy chain, it comprises the aminoacid sequence of SEQ ID NO:1; With

B) modified heavy chain, it comprises the aminoacid sequence of SEQ ID NO:2;

Or

A) modified heavy chain, it comprises the aminoacid sequence of SEQ ID NO:3; With

B) modified heavy chain, it comprises the aminoacid sequence of SEQ ID NO:4;

Or

A) modified heavy chain, it comprises the aminoacid sequence of SEQ ID NO:5; With

B) modified heavy chain, it comprises the aminoacid sequence of SEQ ID NO:6;

Or

A) modified heavy chain, it comprises the aminoacid sequence of SEQ ID NO:7; With

B) modified heavy chain, it comprises the aminoacid sequence of SEQ ID NO:8;

Or

A) modified heavy chain, it comprises the aminoacid sequence of SEQ ID NO:9; With

B) modified heavy chain, it comprises the aminoacid sequence of SEQ ID NO:10;

Or

A) modified heavy chain, it comprises the aminoacid sequence of SEQ ID NO:11; With

B) modified heavy chain, it comprises the aminoacid sequence of SEQ ID NO:12.

In one aspect of the invention, monovalent antigen binding protein according to the present invention is characterised in that, a) and b) modified heavy chain be the IgG1 isotype, and antigen-binding proteins is afucosylated, has the Fucose amount at 80% or lower (preferred 65% to 5%) of oligosaccharides (sugar) total amount at Asn297 place.

The present invention also comprises the method for preparation according to monovalent antigen binding protein of the present invention,

It comprises following steps

A) use the carrier transformed host cell, described carrier comprises the nucleic acid molecule of coding according to monovalent antigen binding protein of the present invention

B) under the condition that allows synthetic described monovalent antigen binding protein molecule, cultivate host cell; With

C) from described culture, reclaiming described monovalent antigen binding protein molecule.

The present invention also comprises nucleic acid, and it is encoded according to monovalent antigen binding protein of the present invention.

The present invention also comprises carrier, and it comprises the nucleic acid of coding according to monovalent antigen binding protein of the present invention.

The present invention also comprises host cell, and it comprises described carrier.

The present invention also comprises the composition according to monovalent antigen binding protein of the present invention, preferred agents or diagnosis composition.

The present invention also comprises pharmaceutical composition, and it comprises according to monovalent antigen binding protein of the present invention and at least a pharmaceutically useful vehicle.

The present invention also comprises patient's the method that treatment needs therapy, described method feature be to patient's administering therapeutic significant quantity according to monovalent antigen binding protein of the present invention.

Antigen-binding proteins according to the present invention is based on following principle, and namely VL-CH1-CH2-CH3 and VH-CL-CH2-CH3 chain only form heterodimer, and can not form the homodimer by product that is difficult to separate with analog structure and molecular weight.The effect of this modification not only mainly is to reduce by product, and is that the only by product that forms becomes the high molecular tetramer (Fig. 1 D) from the homodimer by product with similar size.Then by SEC or other molecular weight isolation technique, can easily remove this high molecular tetramer.

Because molecular weight (molecular weight approximately doubles) is different with structure, can easily separate the dimer by product (Fig. 1 D) of formation.Therefore can purifying and without introducing other modifications (for example label is introduced in heredity).

Also find, monovalent antigen binding protein according to the present invention has valuable feature, and biological example learns or pharmacological activity (for example ADCC, or antibionts activity and shortage are to activity resistent).It can be used for for example treating disease, for example cancer.Monovalent antigen binding protein also has highly valuable pharmacokinetic performance (transformation period (term t1/2) or AUC) for example.

Accompanying drawing is described

Figure 1A) based on the schematic diagram according to monovalent antigen binding protein of the present invention (being abbreviated as MoAb) with CH1-CL Domain swapping of VL-CH1-CH2-CH3 and VH-CL-CH2-CH3 chain.B) in the CH3 structural domain, comprise the schematic diagram according to MoAb of the present invention of knot hand-hole (knob-into-hole).C) schematic diagram of dimerization monovalent antigen binding protein (as the MoAb dimer that by product forms, it,, because structure is different with molecular weight, can easily separate).

Fig. 2 A) univalent antibody (for example describing in US2004/0033561) and B of VL-CL-CH2-CH3 and VH-CH1-CH2-CH3 chain) schematic diagram of the dimer by product (for example describing in WO2007/048037) that is difficult to separate in conjunction with non-activity of VL-CL-CH2-CH3 chain.

The biochemistry of Fig. 3 MoAb c-Met (c-Met5D5MoAb (" wt ")) characterizes.(A) antigen-binding proteins of isolated protein A purifying on the Superdex20026/60 post.The corresponding MoAb (3) in single peak, MoAb dimer (2) and aggregation fraction (1).(B) merge peak fraction (1,2,3) carry out SDS-PAGE under non-reduced and reductive condition.With Coomassie blue dyeing polyacrylamide gel.

The biochemistry of Fig. 4 unit price MoAb IGF1R (IGF1R AK18MoAb (" wt ")) characterizes.(A) antigen-binding proteins of isolated protein A purifying on the Superdex20026/60 post.The corresponding MoAb (2) in single peak and MoAb dimer (1).(B) merge peak fraction (1,2) carry out SDS-PAGE under non-reduced and reductive condition.With Coomassie blue dyeing polyacrylamide gel.C) by SEC-MALLS, study the molecular weight of peak fraction 1 and 2.Peak 2 is accredited as to monovalent antigen binding protein MoAb IGF1R.

The biochemistry of Fig. 5 MoAb Her3 (Her3205MoAb (" wt ")) characterizes.(A) antibody of isolated protein A purifying on the Superdex20026/60 post.The corresponding MoAb (3) in single peak, MoAb dimer (2) and aggregation fraction (1).(B) merge peak fraction (1,2,3) carry out SDS-PAGE under non-reduced and reductive condition.With Coomassie blue dyeing polyacrylamide gel.

The biochemistry that Fig. 6 has the MoAb Her3 (Her3205MoAb KiH) of KiH sudden change characterizes.(A) antigen-binding proteins of isolated protein A purifying on the Superdex20026/60 post.(B) merge peak fraction carry out SDS-PAGE under non-reduced and reductive condition.With Coomassie blue dyeing polyacrylamide gel.

The biochemistry that Fig. 7 has the MoAb IGF1R (IGF1R AK18MoAb KiH) of KiH sudden change characterizes.(A) antibody of isolated protein A purifying on the Superdex20026/60 post.The corresponding MoAb (2) in single peak and MoAb dimer (1).(B) merge peak fraction (1,2) carry out SDS-PAGE under non-reduced and reductive condition.With Coomassie blue dyeing polyacrylamide gel.

The biochemistry that Fig. 8 has the MoAb c-Met (c-Met5D5MoAb KiH) of KiH sudden change characterizes.(A) antibody of isolated protein A purifying on the Superdex20026/60 post.(B) merge peak fraction carry out SDS-PAGE under non-reduced and reductive condition.With Coomassie blue dyeing polyacrylamide gel.

The c-Met receptor phosphorylation of Fig. 9 in the A549 cell measured.Lacking or having c-Met binding antibody or a c-Met5D5MoAb (" wt ")) time with HGF, stimulate the A549 cell.Total cell lysate is carried out to Diagnosis of Sghistosomiasis scores and analyses.Asterisk is marked at phosphoric acid between 2 non-specific bands-c-Met band.

Figure 10 MoAb c-Met (c-Met5D5MoAb (" wt "))), with the Cell binding of A549 cell, use flow cytometry.The dilution series of the antibody of A549 cell and indication is hatched.Use is in conjunction with the two anti-antibody that manifest combination of the coupling fluor of Fc.

The schematic diagram that Figure 11 measures for the surface plasma resonance of the binding affinity of analyzing monovalent antigen binding protein IGF1R AK18MoAb (" wt ").

The Cell binding of Figure 12 MoAb IGF-1R (IGF1R AK18MoAb (" wt ")) and A549 cell, use flow cytometry.The dilution series of the antibody of A549 cell and indication is hatched.Use is in conjunction with the two anti-antibody that manifest combination of the coupling fluor of Fc.

Figure 13 ADCC measures, and uses (non-glycoengineered) (non-ge) IGF1R Mab and (ge) IGF1R Mab of parent's sugar transformation and the monovalent antigen binding protein IGF1R MoAb (IGF1R AK18MoAb (" wt ")) of non-sugar transformation of the non-sugar transformation of parent.There is the non-ge IGF1R of parent Mab (=1), when parent ge IGF1R Mab (=2) and non-ge monovalent antigen binding protein IGF1R MoAb (=3), hatching the peripheral blood lymphocytes of donor source (PBMC) and prostate cancer cell (DU145) are hatched.

Figure 14 is being hatched the internalization of rear assessment IGF-1R with parent IGF-1R IgG1 antibody and monovalent antigen binding protein IGF1R MoAb (IGF1R AK18MoAb (" wt ")), data presentation is when monovalent antigen binding protein IGF1R MoAb (IGF1R AK18MoAb (" wt ")) is combined, and the internalization of IGF-1R is being tired and definitely reduced aspect internalization.

Figure 15 is being hatched the autophosphorylation of the IGF-1R that rear assessment IGF-1 induces with IGF-1R IgG1 antibody and monovalent antigen binding protein IGF1R MoAb (IGF1R AK18MoAb (" wt ")), data presentation is when monovalent antigen binding protein IGF1R MoAb (IGF1R AK18MoAb (" wt ")) is combined, and the autophosphorylation of the IGF-1R that IGF-1 induces reduces aspect tiring.

Figure 16 is by the gathering tendency of DLS time course experimental evaluation monovalent antigen binding protein IGF1R MoAb (IGF1R AK18MoAb (" wt ")).During 5 days, can't detect measurable increase of hydrodynamic radius (Rh) of the monomer fraction (seeing Fig. 4) of separation.

Figure 17 is after de-glycosylation and under non-reduced condition, and the ESI-MS of monovalent antigen binding protein IGF1R MoAb (IGF1R AK18MoAb (" wt ")) composes.

Figure 18 is after de-glycosylation and reduction, and the ESI-MS of IGF-1R monovalent antigen binding protein IGF1R MoAb (IGF1R AK18MoAb (" wt ")) composes.

Detailed Description Of The Invention

In a preferred embodiment of the invention, can pass through " knot hand-hole " (" kNobs- iNto- hOles ") (KiH) technology change the CH3 structural domain of monovalent antigen binding protein according to the present invention, described technology is at for example WO96/027011, Ridgway, J.B., wait the people, Protein Eng.9 (1996) 617-621; And Merchant, A.M., wait the people, in Nat Biotechnol16 (1998) 677-681, with some examples, describes in detail.In this method, the interactive surfaces that changes 2 CH3 structural domains contains the allos dimerization of 2 heavy chains of these two CH3 structural domains with increase.Each of (2 heavy chain) 2 CH3 structural domains can be " knot ", and another is " hole ".The effect of this modification is significantly to have reduced high molecular tetramer by product.

The introducing disulphide bridges is further stablized heterodimer, and (Merchant, A.M. wait the people, Nature Biotech16 (1998) 677-681; Atwell, S., wait the people, J.Mol.Biol.270 (1997) 26-35) and improve output.

Therefore, in one aspect of the invention, the feature of described monovalent antigen binding protein also is

The structural domain of the CH3 of the heavy chain of full length antibody a) and b) each comfortable interface of CH3 structural domain of modified heavy chain of full length antibody contact, described interface comprises the original interface between antibody CH3 structural domain;

I) change the CH3 structural domain of a heavy chain,

With

Ii) change the CH3 structural domain of another heavy chain,

Preferably, described amino-acid residue with larger side chain volume is selected from arginine (R), phenylalanine (F), tyrosine (Y), tryptophane (W).

Preferably, described amino-acid residue with smaller side chain volume is selected from L-Ala (A), Serine (S), Threonine (T), α-amino-isovaleric acid (V).

In one aspect of the invention, by introducing halfcystine (C) two CH3 structural domains of the further change of amino acid as the corresponding position at each CH3 structural domain, make between two CH3 structural domains and can form disulphide bridges.

In a preferred embodiment, described monovalent antigen binding protein comprises the T366W sudden change in the CH3 structural domain of " knot chain ", and comprises T366S in the CH3 of " pore chain " structural domain, L368A, Y407V sudden change.Also can use the extra interchain disulphide bridges (Merchant between the CH3 structural domain, A.M., Deng the people, Nature Biotech16 (1998) 677-681), for example by in the CH3 structural domain of " knot chain ", introducing the Y349C sudden change and in the CH3 of " pore chain " structural domain, introducing the E356C sudden change or the S354C sudden change.therefore in another preferred embodiment, described monovalent antigen binding protein comprises Y349C in one of 2 CH3 structural domains, the T366W sudden change, with in another of 2 CH3 structural domains, comprise E356C, T366S, L368A, the Y407V sudden change, or described monovalent antigen binding protein comprises Y349C in one of 2 CH3 structural domains, the T366W sudden change, with in another of 2 CH3 structural domains, comprise S354C, T366S, L368A, Y407V sudden change (disulphide bridges between the extra Y349C sudden change in a CH3 structural domain and the extra E356C in another CH3 structural domain or S354C mutant form chaining) (all the time according to Kabat EU index number).But optional or additionally, also can use other knot hand-hole technology of describing in EP1870459A1.The preferred example of described monovalent antigen binding protein is the R409D in the CH3 structural domain of " knot chain "; K370E sudden change and the D399K in the CH3 of " pore chain " structural domain; E357K sudden change (all the time according to Kabat EU index number).

In another preferred embodiment, described monovalent antigen binding protein is included in T366W sudden change and the T366S in the CH3 of " pore chain " structural domain in the CH3 structural domain of " knot chain ", L368A, Y407V sudden change, and be included in extraly the R409D in the CH3 structural domain of " knot chain "; K370E sudden change and the D399K in the CH3 of " pore chain " structural domain; The E357K sudden change.

In another preferred embodiment, described monovalent antigen binding protein is included in the Y349C in one of 2 CH3 structural domains, the T366W sudden change, with the S354C in another of 2 CH3 structural domains, T366S, L368A, the Y407V sudden change, or described monovalent antigen binding protein is included in the Y349C in one of 2 CH3 structural domains, T366W sudden change, and the S354C in another of 2 CH3 structural domains, T366S, L368A, Y407V sudden change, and be included in extraly the R409D in the CH3 structural domain of " knot chain "; K370E sudden change, and the D399K in the CH3 of " pore chain " structural domain; The E357K sudden change.

B) modified heavy chain, it comprises the aminoacid sequence of SEQ ID NO:2.

B) modified heavy chain, it comprises the aminoacid sequence of SEQ ID NO:4.

B) modified heavy chain, it comprises the aminoacid sequence of SEQ ID NO:6.

B) modified heavy chain, it comprises the aminoacid sequence of SEQ ID NO:8.

B) modified heavy chain, it comprises the aminoacid sequence of SEQ ID NO:10.

B) modified heavy chain, it comprises the aminoacid sequence of SEQ ID NO:12.

Term used herein " antibody " expression is by two heavy chain of antibody and two full length antibodies (seeing Fig. 1) that light chain of antibody forms.The heavy chain of full length antibody is polypeptide, it is held to the C-extreme direction and comprises heavy chain of antibody variable domains (VH), heavy chain of antibody constant domain 1 (CHI), antibody hinge region (HR), heavy chain of antibody constant domain 2 (CH2), heavy chain of antibody constant domain 3 (CH3) from N-, is abbreviated as VH-CH1-HR-CH2-CH3; Randomly comprise heavy chain of antibody constant domain 4 (CH4), in the situation that antibody is the IgE hypotype.Preferably, the heavy chain of full length antibody is polypeptide, and it is held to the C-extreme direction and comprise VH, CHI, HR, CH2 and CH3 from N-.The light chain of full length antibody is polypeptide, and it is held to the C-extreme direction and comprise light chain of antibody variable domains (VL), light chain of antibody constant domain (CL) from N-, is abbreviated as VL-CL.Light chain of antibody constant domain (CL) can be κ (kappa) or λ (lambda).Antibody chain links together by disulfide linkage between the polypeptide between (namely light and heavy chain between) between CL structural domain and CH1 structural domain and full length antibody heavy chain hinge area.The example of typical full length antibody is IgG (for example IgG1 and IgG2) for example, IgM, IgA, the natural antibody of IgD and IgE.Can be from single species according to antibody of the present invention, people for example, or it can be chimeric or humanized antibody.Full length antibody according to the present invention comprises 2 antigen binding sites, each by VH and VL to forming, their (first) antigen that all specific binding is identical.By following modification, from these full length antibodies, obtain monovalent antigen binding protein of the present invention: a) by the VH structural domain being replaced with to the VL structural domain of described antibody, modify the first heavy chain of described antibody; And b), by the CHI structural domain being replaced with to the CL structural domain of described antibody, modify the second heavy chain of described antibody.Therefore the monovalent antigen binding protein that obtains comprises 2 modified heavy chains and there is no light chain.

Described heavy or C-light chain of the weight of described full length antibody or the C-of light chain end expression holds last amino acid.

The zone of term used herein " binding site " or " antigen binding site " the expression actual binding partner of antigen-binding proteins according to the present invention (for example antigen or its antigen fragment), and it is derived from antibody molecule or its fragment (for example Fab fragment).Antigen binding site according to the present invention comprises heavy chain of antibody variable domains (VH) and light chain of antibody variable domains (VL).

The antigen binding site of specific binding expectation antigen (be VH/VL to) can be derived from a) known antibodies or the b of antigen) new antibodies or the antibody fragment that obtain by the de novo synthesis immunization method, particularly use antigen protein or nucleic acid or its fragment, or pass through phage display.

The antigen binding site of monovalent antigen binding protein of the present invention comprises 6 complementary determining regions (CDR), and it is to participate in various degree the avidity of antigen binding site.3 weight chain variable domain C DR (CDRH1, CDRH2 and CDRH3) and 3 light chain variable domain C DR (CDRL1, CDRL2 and CDRL3) are arranged.By the relatively more definite CDR with aminoacid sequence compiling database and the scope of framework region (FR), in described database, according to the variability between sequence, these zones have been defined.

Antibodies specific refers to the selectivity identification of antibody to the specific antigen epi-position.For example natural antibody is monospecific.Bi-specific antibody is the antibody with 2 kinds of different antigen-binding specificities.Monovalent antigen binding protein according to the present invention is the epi-position of " monospecific " and each antigen of specific binding.

The term " valency " that uses in this application is illustrated in the binding site of the given number that exists in antibody molecule.For example natural antibody has 2 binding sites, is divalence.Term " monovalent antigen binding protein " expression only comprises the polypeptide of an antigen binding site.

Full length antibody of the present invention comprises the constant region for immunoglobulin of one or more immunoglobulin classes.Immunoglobulin class comprises IgG, IgM, and IgA, IgD and IgE classification (or isotype), and in the situation that IgG and IgA comprise its subclass not (or hypotype).In preferred embodiments, full length antibody of the present invention and therefore monovalent antigen binding protein of the present invention have the constant domain structure of IgG classification antibody.

Term used herein " monoclonal antibody " or " monoclonal antibody combination " refer to the antibody molecule goods that single seed amino acid forms.

Term " chimeric antibody " refers to comprise the ，Ji land, variable region and the antibody that is derived from least part of constant region of different sources or species from a kind of source or species, usually by recombinant DNA technology, prepares.The chimeric antibody that preferably comprises mouse variable region and human constant region.Other preferred forms of " chimeric antibody " that the present invention is contained are following forms, wherein the constant region of the relatively original antibody of constant region has been modified or has been changed to produce according to performance of the present invention, particularly the performance of relevant C1q combination and/or Fc acceptor (FcR) combination.Such chimeric antibody claims again " antibody of classification conversion ".Chimeric antibody is to comprise the DNA section of the immune globulin variable region of encoding and the expression product of the immunoglobulin gene of the DNA section of coding constant region for immunoglobulin.The method that produces chimeric antibody comprises conventional recombinant DNA and Gene transfer techniques, and this is well known in the art.See for example Morrison, S.L., wait the people, Proc.NatI.Acad.Sci.USA81 (1984) 6851-6855; US5,202,238 and US5,204,244.

Term " humanized antibody " refers to following antibody, and framework or complementary determining region that its middle frame or " complementary determining region " (CDR) are compared parent's immunoglobulin (Ig) are modified, to comprise the not CDR of homospecific immunoglobulin (Ig).In preferred embodiments, mouse CDR is transplanted in the framework region of people's antibody with preparation " humanized antibody ".See for example Riechmann, L., wait the people, Nature332 (1988) 323-327; And Neuberger, M.S., wait the people, Nature314 (1985) 268-270.Particularly preferred CDR is corresponding to the sequence of the description of the above-mentioned antigen of those identification chimeric antibodies.Other forms of " humanized antibody " that the present invention comprises are following forms, the constant region antibody that wherein constant region is relatively original is additionally modified or is changed to produce according to performance of the present invention, particularly the performance of relevant C1q combination and/or Fc acceptor (FcR) combination.

Term used herein " people's antibody " is intended to comprise the antibody with the variable and constant region that is derived from people's germline immunoglobulin sequences.People's antibody is that prior art is known (van Dijk, M.A., and van de Winkel, J.G., Curr.Opin.Chem.Biol.5 (2001) 368-374).Also can in transgenic animal (for example mouse), produce people's antibody, described animal is in the situation that can be at the complete storehouse that lacks endogenous immunoglobulin (Ig) generation people antibody or people's antibody of selection after immunity.In these germ line mutation body mouse, shifting ethnic group and be the immunoglobulin gene array will cause producing people's antibody after antigen is attacked (see for example Jakobovits, A., wait the people, Proc.Natl.Acad.Sci.USA90 (1993) 2551-2555; Jakobovits, A., wait the people, Nature362 (1993) 255-258; Bruggemann, M., wait the people, Year Immunol.7 (1993) 33-40).Also can in phage display library, produce people's antibody (Hoogenboom, H.R., and Winter, G., J.Mol.Biol.227 (1992) 381-388; Marks, J.D., wait the people, J.Mol.Biol.222 (1991) 581-597).(Cole, wait the people, Monoclonal Antibodies and Cancer Therapy, Alan R.Liss, the 77th page (1985) also can to use the people's such as the people such as Cole and Boerner technology to prepare human monoclonal antibodies; And Boerner, P., wait the people, J.Immunol.147 (1991) 86-95).As what in chimeric and humanized antibody according to the present invention, mentioned, term used herein " people's antibody " also comprises such antibody, it is modified to produce according to performance of the present invention in constant region, particularly relevant C1q in conjunction with and/or the performance of FcR combination, for example, by " classification conversion ", namely change or sudden change Fc part (for example from IgG1 to IgG4 and/or IgG1/IgG4 sudden change).

Term " recombinant human antibody " is intended to comprise everyone antibody for preparing, expresses, produces or separate by recombinant means as used in this article, for example from host cell, for example NS0 or Chinese hamster ovary celI or the antibody from separating human immunoglobulin gene's transgenic animal (for example mouse), or the recombinant expression vector that uses transfection the to advance host cell antibody of expressing.Such recombinant human antibody has the variable and constant region that is in the rearrangement form.Recombinant human antibody according to the present invention is carried out to body endosome Hypermutation.Therefore, the aminoacid sequence in the VH of recombinant antibodies and VL district is such sequence, although its be derived from and with people's germline VH and VL Serial relation, may not naturally be present in the people's antibody germline storehouse in body.

Each light and heavy chain pair of the combination of antibody and antigen is participated in " variable domains " used herein (light chain variable structural domain (VL), variable region of heavy chain (VH)) expression directly.Light and structural domain heavy chain of variable people has identical general structure, and each structural domain comprises extensively conservative framework (FR) district of 4 sequences, and described framework region is by 3 " hypervariable region " (or complementary determining region, CDR) connection.Framework region adopts the beta sheet conformation, and CDR can form the ring that connects the beta sheet structure.CDR in every chain remains its three-dimensional structure by framework region, and forms antigen binding site together with CDR from other chains.Antibody weighs and particularly important plays in light chain CDR3 district in the binding specificity/avidity according to antibody of the present invention, and therefore another object of the present invention is provided.

When using in this article, term " hypervariable region " or " antigen-binding portion thereof of antibody " refer to the amino-acid residue of the antibody of responsible antigen combination.Hypervariable region comprises the amino-acid residue from " complementary determining region " or " CDR "." framework " or " FR " district is those variable domains zones of non-hypervariable region defined herein residue.Therefore, the light and heavy chain of antibody comprises structural domain FR1, CDR1, FR2, CDR2, FR3, CDR3 and FR4 from N-to C-end.CDR on every chain is separated by these framework amino acids.Especially, the CDR3 of heavy chain is in conjunction with the maximum zone of contribution to antigen.According to Kabat, wait the people, Sequences of Proteins of Immunological Interest, the 5th edition, Public Health Service, National Institutes of Health, Bethesda, the standard definition of MD (1991) is determined CDR and FR district.

Term used herein " combination " or " specific binding " refer in external test, preferably at the plasma resonance of the wild-type antigen that uses purifying, measure (BIAcore, GE-Healthcare Uppsala, Sweden) in, the combination of monovalent antigen binding protein and epitope.By term ka (rate constant of antibody from associating the antibody/antigen mixture), k _D(dissociation constant) and K _D(k _D/ ka) definition combination avidity.In conjunction with or specific binding represent 10 ^-8Mol/l or lower, preferred 10 ^-9M to 10 ^-13Binding affinity (the K of mol/l _D).Therefore, monovalent antigen binding protein according to the present invention is combined with following each antigen-specific, namely has 10 ^-8Mol/l or lower, preferred 10 ^-9M to 10 ^-13Binding affinity (the K of mol/l _D) specific antigens.

Can measure by BIAcore the combination of (GE-Healthcare Uppsala, Sweden) research monovalent antigen binding protein and Fc γ RIII.By term ka (rate constant of antibody from associating the antibody/antigen mixture), k _D(dissociation constant) and K _D(k _D/ ka) definition combination avidity.

Term " epi-position " comprise can with any polypeptide determinant of monovalent antigen binding protein specific binding.In certain embodiments; the epi-position determinant comprises the chemically reactive surface base of molecule, for example amino acid, sugared side chain, phosphoryl or alkylsulfonyl, and in certain embodiments; the epi-position determinant can have specific Three Dimensions Structure, and/or specific charge characteristic.Epi-position is by the antigen zone of unit price antigen-binding proteins combination.

In certain embodiments, when antibody is preferably identified its target antigen in protein and/or macromolecular complex mixture, claim antibody to be combined with antigen-specific.

In other embodiments, monovalent antigen binding protein according to the present invention is characterised in that, described full length antibody is human IgG1's subclass, or has human IgG1's subclass of sudden change L234A and L235A.

In other embodiments, monovalent antigen binding protein according to the present invention is characterised in that, described full length antibody is human IgG2's subclass.

In other embodiments, monovalent antigen binding protein according to the present invention is characterised in that, described full length antibody is human IgG 3 subclass.

In other embodiments, monovalent antigen binding protein according to the present invention is characterised in that, described full length antibody is human IgG 4 subclass, or has human IgG 4 subclass (claiming again IgG4SPLE) of additional mutations S228P and L235E.

Use in this application the structural domain summation of the antibody of the non-variable region of term " constant region " expression.Constant region is not participated in the antigen combination directly, but has showed multiple effector function.The aminoacid sequence that depends on its CH, by antibody classification (claiming again isotype): IgA, IgD, IgE, IgG and IgM, some in these types can be further divided into subclass (claiming again isotype), for example IgG1, IgG2, IgG3 and IgG4, IgA1 and IgA2.The CH of corresponding different antibodies type is called as respectively α, δ: ε, γ and μ.The constant region of light chain (CL) that can find in all 5 kinds of Antibody types is called as κ (kappa) and λ (lambda).

Use in this application term " to be derived from the constant region in people source " and represent IgG1, IgG2, IgG3, or the constant heavy chain district of people's antibody of IgG4 subclass and/or constant light chain κ or λ district.Such constant region is that prior art is known, for example at Kabat, and E.A., middle description (is shown in for example Johnson, G. and Wu, T.T., Nucleic Acids Res.28 (2000) 214-218; Kabat, E.A., wait the people, Proc.Natl.Acad.Sci.USA72 (1975) 2785-2788).

Although the antibody of IgG4 subclass shows Fc acceptor (the Fc γ RIIIa) combination that reduces, the antibody of other IgG subclass shows strong combination.Yet, if change residue Pro238, Asp265, Asp270, Asn297 (loss Fc carbohydrate), Pro329, Leu234, Leu235, Gly236, Gly237, Ile253, Ser254, Lys288, Thr307, Gln311, Asn434 and His435, also provide the Fc receptors bind (Shields of reduction, R.L., wait the people, J.Biol.Chem.276 (2001) 6591-6604; Lund, J., wait the people, and FASEB is (1995) 115-119 J.9; Morgan, A., wait the people, Immunology86 (1995) 319-324; EP0307434).

In one embodiment, antibody according to the present invention is compared the FcR combination that IgG1 antibody has reduction, and the FcR of total length parental antibody and IgG4 subclass or IgG1 or IgG2 subclass is in conjunction with relevant, has S228, L234, L235 and/or D265 sudden change, and/or comprise the PVA236 sudden change.In one embodiment, the sudden change in the total length parental antibody is S228P, L234A, L235A, L235E and/or PVA236.In another embodiment, the sudden change in the total length parental antibody is S228P and L235E in IgG4, in IgG1, is L234A and L235A.

The constant region of antibody is participated in ADCC (cytotoxicity of antibody dependent cellular mediation) and CDC (CDC) directly.Complement activation (CDC) be by the constant region of complement factor C1q and most of IgG Subclass of antibodies in conjunction with initial.The combination of C1q and antibody is to cause by the protein-protein interaction of determining on so-called binding site.Such constant region binding site is that prior art is known, and at for example Lukas, T.J., wait the people, J.Immunol.127 (1981) 2555-2560; Bunkhouse, R. and Cobra, J.J., Mol.Immunol.16 (1979) 907-917; Burton, D.R., wait the people, Nature288 (1980) 338-344; Thomason, J.E., wait the people, Mol.Immunol.37 (2000) 995-1004; Idiocies, E.E., wait the people, J.Immunol.164 (2000) 4178-4184; Hearer, M., wait the people, J.Virol.75 (2001) 12161-12168; Morgan, A., wait the people, Immunology86 (1995) 319-324; With in EP0307434, describe.These constant region binding sites for example pass through amino acid L234, L235, and D270, N297, E318, K320, K322, P331 and P329 (according to the EU index number of Kabat) characterize.

Term " cytotoxicity (ADCC) of antibody dependent cellular mediation " refers to when having the effector cell by the cracking of the people target cell according to antibody of the present invention.Preferably by when having the effector cell, using according to antibody treatment antigen presentation cell preparation of the present invention and measure ADCC, described effector cell is the PBMC of for example fresh separated or from the effector cell of the purifying of buffy coat, as the NK clone of monocyte or natural killer (NK) cell or permanent growth.

Have been found that unexpectedly antigen-binding proteins according to the present invention compares its parent's full length antibody and shown improved ADCC performance.Further do not modify the Fc part, for example the sugar transformation has just realized these improved ADCC effects.Term " CDC (CDC) " the expression Fc by complement factor C1q and most of IgG Subclass of antibodies partly in conjunction with initial process.The combination of C1q and antibody is to cause by the protein-protein interaction of determining on so-called binding site.Such Fc part binding site is prior art known (on seeing).For example pass through amino acid L234, L235, D270, N297, E318, K320, K322, P331 and P329 (according to the EU index number of Kabat) characterize these Fc part binding sites.IgG1, the antibody of IgG2 and IgG3 subclass usually show the complement activation that comprises C1q and C3 combination, and IgG4 not the activating complement system also not in conjunction with C1q and/or C3.

As at Umana, P., wait the people, and Nature Biotechnol.17 (1999) 176-180 and US6 describe in 602,684, and the cell-mediated effector function of monoclonal antibody can strengthen by transforming its oligosaccharide compositions.The treatment antibody that the most often uses, IgG1 type antibody is glycoprotein, its Asn297 place in each CH2 structural domain has the glycosylation site that conservative N-connects.The two branch's oligosaccharides that are attached to 2 kinds of complexity of Asn297 are imbedded between the CH2 structural domain, with polypeptide backbone, form a large amount of the contact, and there is antagonist mediation effector function in it, for example the cytotoxicity (ADCC) of antibody dependent cellular mediation is vital (Lifely, M.R., Deng the people, Glycobiology5 (1995) 813-822; Jefferis, R., wait the people, Immunol.Rev.163 (1998) 59-76; Wright, A., and Morrison, S., L., Trends Bioteehnol.15 (1997) 26-32).Umana, P., Deng people Nature Biotechnol.17 (1999) 176-180 and WO99/54342, show, in Chinese hamster ovary (CHO) cell, cross expression β (1,4)-N-acetyl-glucosamine transferase I II (" GnTIII "), the glycosyltransferase that a kind of catalysis two branches' oligosaccharides form, significantly improved the external ADCC activity of antibody.The change that the Asn297 carbohydrate forms or its are eliminated the combination of also impact and Fc γ R and C1q, and (Umana, P. wait the people, Nature Biotechno1.17 (1999) 176-180; Davies, J., wait the people, Biotechnol.Bioeng.74 (2001) 288-294; Mimura, Y., wait the people, J.Biol.Chem.276 (2001) 45539-45547; Radaev, S., wait the people, J.Biol.Chem.276 (2001) 16478-16483; Shields, R., L., wait the people, J.Biol.Chem.276 (2001) 6591-6604; Shields, R., L., wait the people, J.Biol.Chem.277 (2002) 26733-26740; Simmons, L., C., wait the people, J.Immunol.Methods263 (2002) 133-147).

In one aspect of the invention, monovalent antigen binding protein according to the present invention is characterised in that, a) and b) modified heavy chain be the IgG1 type, and antigen-binding proteins is afucosylated, has 80% or lower Fucose amount in oligosaccharides (sugar) total amount at Asn297 place.

In one embodiment, antigen-binding proteins is afucosylated, has 65% to 5% Fucose amount in oligosaccharides (sugar) total amount at Asn297 place.

Term " afucosylated antigen-binding proteins " refers to have in Asn297 position, Fc district the IgG1 of the glycosyl pattern with change of fucosyl residues level of reduction or the antigen-binding proteins of IgG3 isotype (preferred IgG1 isotype).The glycosylation of human IgG1 or IgG3 occurs on the Asn297 position, is the two branches complex oligosaccharide glycosylation of core fucosylation, with 2 Gal residues terminations at the most.The amount that depends on end Gal residue, be appointed as G0 by these structures, G1 (α 1,6 or α 1,3) or G2 glycan residue (Raju, T.S., BioProcess Int.1 (2003) 44-53).The CHO type glycosylation of antibody Fc part is for example at Routier, and J.14 F.H., Glycoconjugate describe in (1997) 201-207.In the CHO host cell without sugar-modified recombinant expressed antibody usually in the Asn297 position with at least 85% amount by fucosylation.Should be appreciated that term afucosylated antibody used herein is included in the antibody that there is no Fucose in its glycosylation pattern.As everyone knows, the typical glycosylated residue position in antibody is the l-asparagine (" Asn297 ") of the 297th according to the EU numbering system.

Therefore, afucosylated antigen-binding proteins according to the present invention represents the antibody of IgG1 or IgG3 isotype (preferred IgG1 isotype), and wherein the amount of Fucose is 80% or lower (for example 80% to 1%) (this at least 20% or more oligosaccharides that is illustrated in Asn297 position, Fc district is afucosylated) of oligosaccharides (sugar) total amount of Asn297 position.In one embodiment, the amount of Fucose is 65% or lower (for example 65% to 1%) at the oligosaccharides of Asn297 position, Fc district, in one embodiment, and from 65% to 5%, in one embodiment, from 40% to 20%.According to the present invention, " amount of Fucose " expression is attached to the summation (for example complexity, mixing and high mannose structures) of all oligosaccharides (sugar) of Asn297 relatively, the amount of the described oligosaccharides (Fucose) in oligosaccharides (sugar) chain of Asn297 position, described amount is by the MALDI-TOF mass-spectrometer measurement and with mean value calculation (the relevant detailed procedure of measuring the Fucose amount, be shown in for example WO2008/077546).In addition, in one embodiment, the oligosaccharides in Fc district is two branches.According to afucosylated antibody of the present invention, can in sugar-modified host cell, express, described host cell reaches with the scale that is enough to the oligosaccharides in part fucosylation Fc district the nucleic acid that at least a coding has the polypeptide of GnTIII activity through transformation.In one embodiment, the polypeptide that has a GnTIII activity is fusion polypeptide.Alternatively, can be according to US6,946,292 reduce or eliminate the α 1 of host cell, and 6-fucosyltransferase activity, to produce sugar-modified host cell.Can or by the antibody that 2 kinds of combinations have different fucosylation amounts, pre-determine the amount of antibody fucosylation at least by for example fermentation condition (for example fermentation time).The sugared remodeling method of such afucosylated antigen-binding proteins and correspondence is at WO2005/044859, WO2004/065540, WO2007/031875, Umana, P., Deng the people, Nature Biotechnol.17 (1999) 176-180, WO99/154342, WO2005/018572, WO2006/116260, WO2006/114700, WO2005/011735, WO2005/027966, WO97/028267, US2006/0134709, US2005/0054048, US2005/0152894, WO2003/035835, describe in WO2000/061739.Antigen-binding proteins through the sugar transformation according to the present invention has the ADCC (comparing parent's antigen-binding proteins) of increase.Generation according to methods of other sugar transformations of afucosylated antigen-binding proteins of the present invention at for example Niwa, the people such as R.., J.Immunol.Methods306 (2005) 151-160; Shinkawa, T., wait the people, J.Biol.Chem, 278 (2003) 3466-3473; In WO03/055993 or US2005/0249722, describe.

Therefore one aspect of the present invention be used for the treatment of cancer according to afucosylated antigen-binding proteins of the present invention, it is IgG1 isotype or IgG3 isotype (preferred IgG1 isotype), has the Fucose amount 60% or lower (for example 60% to 1%) of oligosaccharides (sugar) total amount of Ash297 position.Another aspect of the present invention is what to have in 60% or lower Fucose amount of oligosaccharides (sugar) total amount of Ash297 position, and the afucosylated anti-CD20 antibodies of the IgG1 of specific binding CD20 or IgG3 isotype (preferred IgG1 isotype) is for the manufacture of the purposes of the medicine for the treatment of cancer.In one embodiment, the Fucose amount oligosaccharides (sugar) total amount of Asn297 position 60% to 20% between.In one embodiment, the Fucose amount oligosaccharides (sugar) total amount of Asn297 position 60% to 40% between.In one embodiment, the Fucose amount account for the Asn297 position oligosaccharides (sugar) total amount 0% between.

When the residue in mentioning immunoglobulin heavy chain constant region or position, general use " EU numbering system " or " EU index (according to Kabat) " (for example, people such as Kabat, Sequences of Proteins of Immunological Interest, the 5th edition, Public Health Service, National Institutes of Health, Bethesda, MD has reported the EU index in (1991), and it clearly is incorporated herein by reference).

Term " sugar chain has shown that the N-of the Asn297 that is attached to antibody recombinant expressed in Chinese hamster ovary celI connects the feature of glycan " expression, have identical structure and saccharide residue sequence with the same antibody of expressing in the Chinese hamster ovary celI of unmodified (antibody of for example reporting in WO2006/103100) according to the sugar chain of the Asn297 position of total length parental antibody of the present invention except fucosyl residues.

Term " NGNA " the expression saccharide residue NeuGc ALPHA2-3Gal that uses in this application.

Antibody according to the present invention produces by recombinant means.Therefore, one aspect of the present invention is the nucleic acid of coding according to antibody of the present invention, and another aspect is to comprise the cell of described coding according to the nucleic acid of antibody of the present invention.The method that restructuring produces is that prior art is well-known, and is included in the protein expression in protokaryon and eukaryotic cell, and separation antibody also is purified to pharmaceutically useful purity usually subsequently.In order in host cell, to express above-mentioned antibody, by standard method, will encode in the nucleic acid insertion expression vector of each modified light and heavy chain.In suitable protokaryon or eukaryotic host cell such as Chinese hamster ovary celI, NS0 cell, SP2/0 cell, HEK293 cell, COS cell, PER.C6 cell, yeast or Bacillus coli cells, express, and from cell (cell after supernatant or cracking), reclaiming antibody.The general method that produces antibody for recombinating is that prior art is known, and for example at Makrides, S.C., Protein Expr.Purif.17 (1999) 183-202; Geisse, S., wait the people, Protein Expr.Purif.8 (1996) 271-282; Kaufman, R.J., Mol.Biotechnol.16 (2000) 151-161; Werner, R.G., describe in the survey article of Drug Res.48 (1998) 870-880.

By routine immunization sphaeroprotein purifying procedure, for example a-protein-agarose, hydroxyapatite chromatography, gel electrophoresis, dialysis or affinity chromatography are from suitably separating according to monovalent antigen binding protein of the present invention substratum.

Use conventional procedure easily to separate and check order DNA and the RNA of monoclonal antibody of encoding.Hybridoma can be used as the source of such DNA and RNA.In case separated, DNA can be inserted to expression vector, then its transfection is advanced otherwise the host cell that do not produce immunoglobulin (Ig) for example in HEK293 cell, Chinese hamster ovary celI or myeloma cell, to obtain the synthetic of in host cell recombinant monoclonal antibodies.

By in antibody dna, introducing suitable Nucleotide, change, or by Nucleotide, synthesize the aminoacid sequence variant (or mutant) for preparing monovalent antigen binding protein.Yet such modification only can be carried out in very limited scope for example mentioned above.For example, modify and do not change above-mentioned antibody feature (for example IgG isotype and antigen combination), but can improve output, the protein stability of recombinant production or help purifying.

The cell system of term " host cell " the expression any type that uses in this application, it can be transformed to produce according to antibody of the present invention.In one embodiment, use HEK293 cell and Chinese hamster ovary celI as host cell.Representation used herein " cell ", " clone " and " cell culture " are used interchangeably and all these titles comprise the offspring.Therefore, word " transformant " and " cell through transforming " comprise primary described cell and are derived from its culture, no matter transfer number.Also should be appreciated that all offsprings out of true on the DNA content is identical owing to deliberately or unintentionally suddenling change.Also comprise and having with original in the cell of conversion identical function or bioactive variant offspring be used to screening.

For example, Barnes, L.M., wait the people, Cytotechnology32 (2000) 109-123; Barnes, L.M., wait the people, and Biotech.Bioeng.73 (2001) 261-270 has described the expression in the NS0 cell.For example, Durocher, Y., wait the people, and Nucl.Acids.Res.30 (2002) E9 has described transient expression.Orlandi, R., wait the people, Proc.Natl.Acad.Sci.USA86 (1989) 3833-3837; Carter, P., wait the people, Proc.Natl.Acad.Sci.USA89 (1992) 4285-4289; And Norderhaug, L., wait the people, and J.Immuno1.Methods204 (1997) 77-87 has described the clone of variable domains.Schlaeger, E.-J., and Christensen, K., in Cytotechnology30 (1999) 71-83 and Schlaeger, E.-J., described preferred transient expression system (HEK293) in J.Immunol.Methods194 (1996) 191-199.

The control sequence that is suitable for prokaryotic cell prokaryocyte comprises for example promotor, randomly operon sequence, and ribosome bind site.The known genuine karyocyte utilizes promotor, enhanser and polyadenylation signal.

When nucleic acid was placed in the functional relationship with another kind of nucleotide sequence, it was " effectively connecting ".For example, if presequence or secrete leading DNA and be expressed as the front albumen that participates in the polypeptide secretion, it is effectively to be connected with polypeptid DNA; If promotor or enhanser affect transcribing of sequence, it is effectively to be connected with encoding sequence; If or the position of ribosome bind site help the translation, it is effectively to be connected with encoding sequence.Usually, DNA sequence dna that " effectively connecting " expression connects is continuous, and, in the situation that secretion property leader sequence, be continuous in in-frame.Yet enhanser must not be continuous.By in the connection of restriction site easily, completing connection.If such site does not exist, according to conventional practice, use synthetic oligonucleotide adapter or joint.

By standard technique, carry out the purifying of monovalent antigen binding protein to remove cellular component or other pollutents, for example other nucleus or protein (for example by product), described technology comprises that alkali/SDS processes, CsCl shows band, column chromatography, agarose gel electrophoresis and other technologies well known in the art and (sees Ausubel, F., Deng people's (volume), Current Protocols in Molecular Biology, Greene Publishing and Wiley Interscience, New York (1987)).different methods for protein purification is Erecting and improving and widely used, for example use the affinity chromatography (for example a-protein or protein G affinity chromatography) of microprotein, ion exchange chromatography (cationic exchange (carboxymethyl resin) for example, anionresin (amino-ethyl resin) and mixed mode exchange), parent's sulphur absorption (for example using beta-mercaptoethanol and other SH parts), hydrophobic interaction or aromatics adsorption chromatography (for example use phenyl sepharose, aza-arenophilic resin or m-aminophenyl ylboronic acid), the metal chelator affinity chromatography (for example, use Ni (II) and Cu (II) affinitive material), size exclusion chromatography and electrophoresis method are (for example, gel electrophoresis, capillary electrophoresis) (Vijayalakshmi, M.A., Appl.Biochem.Biotech.75 (1998) 93-102).The example of purifying has been described in Fig. 3 to 8 of embodiment 1 and correspondence.

One aspect of the present invention is the pharmaceutical composition that comprises according to antibody of the present invention.Another aspect of the present invention is the purposes of antibody according to the present invention for the manufacture of pharmaceutical composition.Another aspect of the present invention is to manufacture to comprise the method according to the pharmaceutical composition of antibody of the present invention.In yet another aspect, the invention provides composition, pharmaceutical composition for example, its comprise together with pharmaceutical carrier, prepare according to antibody of the present invention.

One embodiment of the invention be used for the treatment of cancer according to monovalent antigen binding protein of the present invention.

Another aspect of the present invention is the described pharmaceutical composition that is used for the treatment of cancer.

One embodiment of the invention are that it is used for the treatment of cancer according to monovalent antigen binding protein of the present invention.

Another aspect of the present invention is the purposes of antibody according to the present invention for the manufacture of the medicine for the treatment of cancer.

Another aspect of the present invention is to use by the patient to the such treatment of needs the method that Antybody therapy according to the present invention suffers from the patient of cancer.

" pharmaceutical carrier " used herein comprise physical compatibility arbitrarily and all solvents, dispersion medium, coating, antibiotic and anti-mycotic agent, etc. blend the delay absorption agent, etc.Preferably, carrier is suitable for intravenously, intramuscular, subcutaneous, parenteral, spinal cord or epidermis and uses (for example by injection or infusion).

Can use composition of the present invention by several different methods known in the art.Those of skill in the art will understand, and route of administration and/or pattern will change according to the result of expectation.In order by some route of administration, to use compound of the present invention, may be coated with compound with the material of avoiding its inactivation, or described material is used jointly with changing the house thing, for example, can be applied in suitable carrier to object, for example the compound in liposome or thinner.Pharmaceutically useful thinner comprises salt solution and aqueous buffer.Pharmaceutical carrier comprises for the aseptic aqueous solution for preparing aseptic injectable solution or dispersion agent or dispersion agent and sterilized powder temporarily.For these media of pharmaceutically active substance and the use of promoting agent, be known in the art.

The mode of administration of phrase used herein " parenteral is used " and " parenteral administration " non-intestines of expression and topical application, usually by injection, include but not limited in intravenously, intramuscular, intra-arterial, sheath, in capsule, in socket of the eye, in heart, intracutaneous, intraperitoneal, under tracheae, subcutaneous, epidermis, under intraarticular, capsule, in subarachnoid, backbone, epidural and breastbone inner injection and infusion.

term cancer used herein refers to proliferative disease, for example lymphoma, Lymphocytic leukemia, lung cancer, non-small cell lung (NSCL) cancer, the bronchioloalveolar cell lung cancer, osteocarcinoma, carcinoma of the pancreas, skin carcinoma, the cancer of head or neck, skin or intraocular melanoma, uterus carcinoma, ovarian cancer, the rectum cancer, the cancer of anal region, cancer of the stomach (stomach cancer), cancer of the stomach (gastric cancer), colorectal carcinoma, mammary cancer, uterus carcinoma, carcinoma of fallopian tube, carcinoma of endometrium, cervical cancer, carcinoma of vagina, the vaginal orifice cancer, Hodgkin's disease (Hodgkin ' s Disease), esophagus cancer, carcinoma of small intestine, the cancer of endocrine system, thyroid carcinoma, parathyroid carcinoma, adrenal carcinoma, soft tissue sarcoma, urethral carcinoma, penile cancer, prostate cancer, bladder cancer, kidney or carcinoma of ureter, renal cell carcinoma, carcinoma of renal pelvis, mesothelioma, hepatocellular carcinoma, cancer of bile ducts, central nervous system (CNS) tumour, spinal cord axle tumour, the brain stem glioma, glioblastoma multiforme, astrocytoma, schwannoma, ependymoma, medulloblastoma, meningioma, squamous cell carcinoma, pituitary adenoma and ewing's sarcoma (Ewings sarcoma), comprise the refractory form of any above-mentioned cancer or the combination of one or more above-mentioned cancers.

These compositions also can comprise adjuvant, for example sanitas, wetting agent, emulsifying agent and dispersion agent.Can and add multiple antibiotic and anti-mycotic agent by above-mentioned sterilizing program, such as p-Hydroxybenzoate, butylene-chlorohydrin, phenol, Sorbic Acid etc. guaranteed the existence of prophylaxis of microbial.Also may wish to comprise isotonic agent at composition, for example sugar, sodium-chlor etc.In addition, can postpone the promoting agent that absorbs by adding, for example aluminum monostearate and gelatin cause the absorption of the prolongation of injectable drug form.

No matter the route of administration of selecting, by ordinary method well known by persons skilled in the art can be suitable the compound of the present invention that uses of hydrated form, and/or pharmaceutical composition of the present invention is formulated as pharmaceutically useful formulation.

Can change the actual dose level of the activeconstituents in pharmaceutical composition of the present invention, to obtain effectively realizing the therapeutic response of expectation under particular patient, composition and mode of administration, and the active principle nontoxic to the patient.Selected dosage level will depend on multi-medicament dynamic metabolism factor, excretion rate, treatment time length, the other drug, compound and/or the material that are used in combination with the particular composition of application, subject patient's age, sex, body weight, the patient's condition, general health and the medical history of specific compound that comprises activity, route of administration, time of application, the application of the particular composition of the present invention of application, and the similar factor known of medical field.

Composition is must be enough aseptic and be fluid, makes composition to send by syringe.Except water, supporting agent is the isotonic buffer salts solution preferably.

Can be by for example using for example Yelkin TTS of coating, in the situation that dispersion agent is by remaining the granular size that needs and remaining suitable mobility by the use tensio-active agent.In many cases, preferably at composition, comprise isotonic agent, for example sugar, many alcohol for example N.F,USP MANNITOL or sorbyl alcohol and sodium-chlor.

Representation used herein " cell ", " clone " and " cell culture " are used interchangeably and all these titles comprise the offspring.Therefore, word " transformant " and " cell through transforming " comprise primary described cell and are derived from its culture, no matter transfer number.Also should be appreciated that all offsprings out of true on the DNA content is identical owing to deliberately or unintentionally suddenling change.Also comprise and having with original in the cell of conversion identical function or bioactive variant offspring be used to screening.When representing different titles, from the context will be apparent.

Term used herein " conversion " refers to carrier/nucleic acid is shifted to the process into host cell.If use the cell that is not difficult to the cell walls obstacle of going beyond as host cell, can be by for example Graham and Van der Eh, the calcium phosphate precipitation method that Virology52 (1978) 546 describes is carried out transfection.Yet, also can use other DNA to be introduced to the method for cell, for example by core, inject or pass through protoplast fusion.If use prokaryotic cell prokaryocyte or comprise the cell that a large amount of cell wallss are constructed, for example, a kind of transfection method is that as Cohen, F.N, wait the people, the calcium processing of the use calcium chloride that PNAS.69 (1972) 7110 describes.

" expression " used herein refers to that transcribed nucleic acid becomes the process of mRNA and/or the mRNA that transcribes (claiming again transcript) to be translated as subsequently the process of peptide, polypeptide or protein.The polypeptide of transcript and coding is referred to as to gene product.If polynucleotide are derived from genomic dna, the expression in eukaryotic cell can comprise the montage of mRNA.

" carrier " is nucleic acid molecule, and the nucleic acid molecule of self-replacation particularly, its nucleic acid molecule by insertion shift into host cell and/or between host cell and shift and insert.Term comprises that major function is that major function is the replicating vector of repetition DNA or RNA, and function is to transcribe and/or translate the expression vector of DNA or RNA by the carrier of DNA or RNA insertion cell (for example chromosomal integration).Also comprise the carrier that surpasses a kind of above-mentioned functions is provided.

" expression vector " is polynucleotide, can be transcribed when it is introduced into the appropriate host cell and be translated as polypeptide." expression system " is often referred to the appropriate host cell that is comprised of expression vector, and described host cell can be brought into play the expression product that function is produced expectation.

Provide following examples, sequence table and figure to help understanding the present invention, true scope of the present invention is stated in the claims of enclosing.Should be appreciated that under the prerequisite that does not deviate from spirit of the present invention and can modify to the flow process of statement.

Sequence table is described

The heavy chain of SEQ ID NO:1c-Met 5D5 MoAb (" wt ")-modified is VL-CH1-CH2-CH3 a)

SEQ ID NO:2c-Met 5D5 MoAb (" wt ")-modified heavy chain b) VH-CL-CH2-CH3

The heavy chain of SEQ ID NO:3IGF1R AK18 MoAb (" wt ")-modified is VL-CH1-CH2-CH3 a)

SEQ ID NO:4IGF1R AK18 MoAb (" wt ")-modified heavy chain b) VH-CL-CH2-CH3

The heavy chain of SEQ ID NO:5Her3 205 MoAb (" wt ")-modified is VL-CH1-CH2-CH3 a)

SEQ ID NO:6Her3 205 MoAb (" wt ")-modified heavy chain b) VH-CL-CH2-CH3

The heavy chain that SEQ ID NO:7c-Met 5D5 MoAb KiH modifies is VL-CH1-CH2-CH3 knot T366W a), S354C

The heavy chain b that SEQ ID NO:8c-Met 5D5 MoAb KiH modifies) VH-CL-CH2-CH3 hole L368A, Y407V, T366S, Y349C

The heavy chain that SEQ ID NO:9IGF1R AK18 MoAb KiH modifies is VL-CH1-CH2-CH3 knot T366W a), S354C

The heavy chain b that SEQ ID NO:10IGF1R AK18 MoAb KiH modifies) VH-CL-CH2-CH3 hole L368A, Y407V, T366S, Y349C

The heavy chain that SEQ ID NO:11Her3 205 MoAb KiH modify is VL-CH1-CH2-CH3 knot T366W a), S354C

The heavy chain b that SEQ ID NO:12Her3 205 MoAb KiH modify) VH-CL-CH2-CH3 hole L368A, Y407V, T366S, Y349C

Experimental arrangement

A. materials and methods:

Recombinant DNA technology

As Sambrook, J., wait the people, Molecular cloning:A laboratory manual; Cold Spring Harbor Laboratory Press, the Application standard method of describing in Cold Spring Harbor, New York (1989) is handled DNA.According to the specification sheets of manufacturers, use molecular biology reagent.

DNA and protein sequence analysis and sequence data management

About human normal immunoglobulin is light and the general information of the nucleotide sequence of heavy chain at Kabat, E.A. wait the people, (1991) Sequences of Proteins of Immunological Interest,, provide in NIHPublication No91-3242 by the 5th edition.(Edelman, G.M. wait the people, PNAS63 (1969) 78-85 according to the EU numbering; Kabat, E.A., wait the people, (1991) Sequences of Proteins of Immunological Interest, the 5th edition, NIH Publication No91-3242) amino acid of numbering antibody chain.Use GCG (Genetics Computer Group, Madison, Wisconsin) software package version 10.2 and Infomax's Vector NTI Advance software group version 8.0 for sequence generation, mapping, analysis, annotation and explanation.

DNA sequencing

By the two strands order-checking of carrying out at SequiServe (Vaterstetten, Germany) and Geneart AG (Regensburg, Germany), measure DNA sequence dna.

Gene is synthetic

By Geneart AG (Regensburg, Germany), by the automatization gene is synthetic, from synthetic oligonucleotide and PCR product, prepare the constant gene segment C of expectation.The constant gene segment C that both sides is had to single restriction enzyme cleavage site is cloned the plasmid into pGA18 (ampR).From plasmid DNA purification the bacterium through transforming and by ultraviolet spectroscopy concentration.By DNA sequencing, verify the DNA sequence dna of the gene fragment of subclone.By gene, synthesize the preparation both sides and have the complete fragment of DNA sequence dna of 2 antibody chains of coding (VH-CL-CH2-CH3 and VL-CH1-CH2-CH3) of 5'HpaI and 3'NaeI restriction site.Synthetic constant gene segment C with coding " knot hand-hole " of 5'-BclI and 3'-NaeI restriction site, heavy chain of antibody of " knot hand-hole " expression in the CH3 structural domain, carries the T366W sudden change and the second antibody heavy chain carries T366S in the CH3 structural domain, L368A and Y407V sudden change.By gene, synthesize the DNA sequence dna that the preparation both sides have the coding " knot hand-hole " of BclI and NaeI restriction site in a similar fashion, be that heavy chain of antibody carries S354C in the CH3 structural domain and T366W suddenlys change and the second antibody heavy chain carries Y349C, T366S, L368A and Y407V sudden change.All constructs are designed to have to 5 '-end DNA sequence dna of coding leading peptide, the secretion of described leading peptide targeting proteins matter in eukaryotic cell.

The structure of expression plasmid

Use all antibody chains of Roche expression vector establishment.Carrier is comprised of following element:

The replication orgin of-Epstein-Barr virus (EBV), oriP,

The replication orgin of-pUC18 carrier, it allows this plasmid to copy in intestinal bacteria

-β-lactamase gene, it gives the amicillin resistance in intestinal bacteria,

-from early stage enhanser and the promotor immediately of human cytomegalic inclusion disease virus (HCMV),

-people 1-immunoglobulin (Ig) Polyadenylation (" poly A ") signal sequence, and

-unique HpaI, BclI and NaeI restriction site.

By gene, synthesize preparation sequentially for immunoglobulin gene and " knot hand-hole " construct of VH-CL-CH2-CH3 and VL-CH1-CH2-CH3 and clone the plasmid into pGA18 (ampR) as mentioned above.With HpaI and NaeI or with BclI and NaeI restriction enzyme (Roche Molecular Biochemicals) digestion, carry pG18 (ampR) plasmid and the Roche expression vector of synthetic DNA section, the row agarose gel electrophoresis of going forward side by side.Then the DNA section of purifying is connected to Roche expression vector HpaI/NaeI or the BclI/NaeI fragment of separation, produces final expression vector.Final expression vector is transformed into to Bacillus coli cells, separates expression plasmid DNA (Miniprep) and carry out restriction enzyme analysis and DNA sequencing.In 150ml LB-Amp substratum, cultivate correct clone, isolated plasmid dna (Maxiprep) again, and by DNA sequencing authentication sequence integrity.

The transient expression of immunoglobulin variants in the HEK293 cell

Use FreeStyle ^TM293 expression systems, express the recombination immunoglobulin variant according to the specification sheets (Invitrogen, USA) of manufacturers by the transient transfection of human embryo kidney 293-F cell.In simple terms, at FreeStyle ^TM293 express in substratum at 37 ℃/8%CO ₂The FreeStyle that lower cultivation suspends ^TMThe 293-F cell.On transfection same day with 1-2x10 ⁶The density of viable cell/ml is seeded in cell in fresh substratum.

Preparation DNA-293fectin in I substratum (Invitrogen, USA) ^TMMixture, use 325 μ l293fectin ^TMEvery kind of plasmid DNA of 250 μ g of (Invitrogen, Germany) and 1:1 mol ratio is for the final transfection volume of 250ml.After transfection 7 days by with centrifugal 30 minutes of 14000g with filter by sterile filters (0.22 μ m) and gather in the crops the cells and supernatant that comprises antibody.Supernatant is stored in to-20 ℃ until purifying.

Alternatively, by transient transfection in the HEK293-EBNA cell, produce antibody.By at supplementary 10% ultralow IgG FCS (foetal calf serum, Gibco), the DMEM of 2mM L-glutaminate (Gibco) and 250 μ g/ml Geneticins (Gibco) (the Eagle substratum of Dulbecco improvement, Gibeo) (human embryonic kidney cell who expresses Epstein-Barr virus nuclear antigen is 293 to the HEK293-EBNA cell of middle adhesion growth of cultivating; American Type Culture Collection ATCC#CRL-10852, Lot.959218) in each expression plasmid of transient cotransfection express antibody.For transfection, with the FuGENE of 4:1 (scope is from 3:1 to 6:1) ^TMReagent (μ l) uses FuGENE with the ratio of DNA (μ g) ^TM6 transfection reagents (Roche Molecular Biochemicals).The plasmid that uses the equimolar ratio example is from separately plasmid expression protein.At the 3rd day, use L-glutaminate ad4mM, glucose [Sigma] and NAA[Gibco] feeder cell.From after transfection, by centrifugal results, comprising the cells and supernatant of bi-specific antibody and be stored in-20 ℃ in the 5th to 11 days.Relevant the general information of recombinant expressed human normal immunoglobulin is at Meissner in HEK293 cell for example, and the people such as P., provide in Biotechnol.Bioeng.75 (2001) 197-203.

The purifying of antibody

Use a-protein-agarose ^TM(GE Healthcare, Sweden) and Superdex200 size exclusion chromatography by affinity chromatography from antibody purification cells and supernatant.Briefly, the cells and supernatant of sterile filtration is applied to PBS damping fluid (10mM Na ₂HPO ₄, 1mM KH ₂PO ₄, 137mM NaCl and 2.7mM KCl, pH7.4) and HiTrap a-protein HP (5ml) post of balance.With level pad, wash away unconjugated protein.Use the 0.1M citrate buffer, pH2.8 wash-out antibody and antibody variants, use 0.1ml1M Tris, and the pH8.5 neutralization comprises the fraction of protein.Then the protein fraction that merges wash-out, with Amicon ultracentrifugation filtration unit (MWCO:30K, Millipore) be concentrated into the volume of 3ml be loaded into and use the 20mM Histidine, 140mM NaCl, the Superdex200HiLoad120ml16/60 of pH6.0 balance or 26/60 gel-filtration column (GE Healthcare, Sweden).Merge to comprise and have the fraction of assembling the antibody purification of thing lower than 5% high molecular, and be stored in-80 ℃ with the aliquots containig of 1.0mg/ml.

The analysis of purified protein

The molar extinction coefficient that use is calculated based on aminoacid sequence, by measuring the protein concn of measuring purified protein example in the optical density(OD) (OD) at 280am place.By the SDS-PAGE in the situation at existence or shortage reductive agent (5mM1,4-dithiothreitol (DTT)), analyze purity and the molecular weight of antibody, and use coomassie brilliant blue staining.According to the specification sheets of manufacturers, use Precast gel system (Invitrogen, USA) (4-12%Tris-glycine gels).Under 25 ℃ at 200mMKH ₂PO ₄, 250mM KCl, use Superdex200 analysis mode size-exclusion column (GE Healthcare, Sweden) by efficient SEC, to analyze the aggregation content of antibody sample in the running buffer of pH7.0.25 μ g protein were injected to post isocratic elution 50 minutes with the flow velocity of 0.5ml/ minute.For stability analysis, the purified protein of 1mg/ml concentration was hatched 7 days at 4 ℃ and 40 ℃, then (for example HP SEC analyzes (purified protein) assessment by efficient SEC.After passing through to remove the N-glycan with peptide-N-Glycosylase F (Roche Molecular Biochemicals) enzymically treat, by NanoElectrospray Q-TOF mass spectrum, confirm the bi-specific antibody that reduces gently and the integrity of the amino acid backbone of heavy chain.

Mass spectrum and SEC-MALLS

Mass spectrum

By electrospray ionization mass spectrum (ESI-MS), measure and confirmed the total deglycosylated quality of antibody.Briefly, be used in 100mM KH2PO4/K2HPO4,50mU N-Glycosylase F (PNGaseF in pH7, ProZyme) to 100 μ g antibody purifications of 2mg/ml protein concn at the most at 37 ℃ of de-glycosylation 12-24 hour, and subsequently by HPLC in the upper desalination of Sephadex G25 post (GE Healthcare).After de-glycosylation and reduction, by ESI-MS, measure each heavy and quality light chain.Briefly, the 50 μ g antibody of 115 μ l and 60 μ l1M TCEP and 50 μ l8M Guanidinium hydrochlorides are hatched to desalination subsequently.Measure the weight that is reduced and total mass and the quality of light chain being equipped with on the Q-Star Elite MS system in NanoMate source by ESI-MS.The mass range of record depends on molecular weight analyte.In general, for the antibody that reduces, mass range is set in from 600-2000m/z, and non-reducing antibody or bispecific molecule are set in from 1000-3600m/z.

SEC-MALLS

Use SEC-MALLS (size exclusion chromatography with multiple angle laser light scattering) to measure the approximate molecular weight of Proteins In Aqueous Solutions.According to light scattering theory, MALLS allows the macromolecular molecular weight of assessment, no matter its molecularity or other supposition.SEC-MALLS is based on passing through SEC chromatography and concentration subsequently and the light activated detector of scattering size (hydrodynamic radius) isolated protein according to protein.SEC-MALLS generally produces and allows clear molecular weight assessment of differentiating the precision of monomer, dimer, tripolymer etc., and prerequisite is that the SEC separation is sufficient.

In this work, use following instrument: Dionex Ultimate3000HPLC; Post: Superose610/300 (GE Healthcare); Elutriant: 1x PBS; Flow velocity: 0.25mL/ minute; Detector: OptiLab REX (Wyatt Inc., Dernbach), MiniDawn Treos (Wyatt Inc., Dernbach).Use Astra software, version 5.3.2.13 calculates molecular weight.Protein mass between 50 and 150 μ g is loaded on post, and uses BSA (Sigma Aldrich) conduct with reference to protein.

Dynamic light scattering (DLS) time course

Make the His/HisCl at 20mM, 140mM NaCl, the sample of the about 1mg/mL of concentration in pH6.0 (30 μ L) filters and enters 384 hole optical sheets (Corning) and cover (Sigma) with 20 μ L paraffin oils by 384 hole screen plates (0.45 μ m hole size).Use DynaPro DLS flat bed reader (Wyatt) under 40 ℃ of constant temperature during 5 days the repeated collection dynamic light scattering data.With Dynamics V6.10 (Wyatt) processing data.

The c-Met phosphorylation assay

At HGF, stimulate the day before yesterday, in each hole of 6 orifice plates, have 5x10e5 A549 cell of inoculation in the RPMI of 0.5%FCS (foetal calf serum).Second day, replace with growth medium the RPMI1 hour that contains 0.2%BSA (bovine serum albumin).Then add 12,5 μ g/mL bi-specific antibodies to substratum incubated cell 15 minutes, then adding final concentration is the HGF (R&amp of 25ng/mL; D, 294-HGN), then hatched 10 minutes.With the ice-cold PBS that contains the 1mM vanadic acid sodium, wash cell one time, then be placed on ice, and with 100 μ L lysis buffer (50mM Tris-ClpH7.5,150mM NaCl, 1%NP40,0.5%DOC, Trypsin inhibitor,Trasylol, 0.5mM PMSF, 1mM vanadic acid sodium) cracking in Tissue Culture Plate.Cell lysate is transferred to the eppendorf centrifuge tube and allows cracking on ice, to proceed 30 minutes.Use BCA method (Pierce) to measure protein concn.At the upper 30-50 μ g lysate that separates of 4-12%Bis-Tris NuPage gel (Invitrogen), the protein transduction on gel is moved on nitrocellulose filter.With the TBS-T closing membrane that contains 5%BSA 1 hour, according to phosphoric acid specificity C-met antibodies (Epitomics, the 2319-1) video picture of the specification sheets of manufacturers for Y1349.With the antibody in conjunction with unphosphorylated c-Met (Santa Cruz, sc-161), again survey immunoblotting.

Her3 (ErbB3) phosphorylation assay

2x10e5 MCF7 cell of inoculation in each hole at 12 orifice plates in complete growth medium (RPMI1640,10%FCS).Allowing cell in 2 days, to grow to 90% converges.Then substratum is replaced with to the hungry substratum that contains 0.5%FCS.Second day supplements each antibody of indication concentration, after 1 hour, adds 500ng/mL to adjust albumen (R& D).Add adjust albumen after culturing cell 10 minutes, then results lysing cell again.Use BCA method (Pierce) to measure protein concn.At the upper separation of 4-12%Bis-Tris NuPage gel (Invitrogen) 30-50 μ g lysate, and the protein transduction on gel is moved on nitrocellulose filter.With the TBS-T closing membrane that contains 5%BSA 1 hour, and with phosphoric acid specificity Her3/ErbB3 antibody (4791, the Cell Signaling) video picture of specific recognition Tyr1289.

FACS

Separate A549 counting.1.5x10e5 cell of inoculation in each hole of conical 96 orifice plates.Eccentric cell (1500rpm, 4 ℃, 5 minutes) also contains in the dilution series thing of each bi-specific antibody in the PBS of 2%FCS (foetal calf serum) incubated cell on ice 30 minutes at 50 μ L.The recentrifuge cell is also washed cell once with the PBS that 200uL contains 2%FCS, the antibody (Jackson 1mmunoresearch, 109116098) of the coupling of the Alexa488 for people Fc of then diluting in containing the PBS of 2%FCS with 5 μ g/mL is incubated cell 30 minutes again.Cell, with the PBS centrifuge washing 2 times that 200 μ L contain 2%FCS, is resuspended in BD CellFix solution (BD Biosciences) and on ice, hatched at least 10 minutes.By flow cytometer (FACS Canto, BD), measure the average fluorescent strength (mfi) of cell.By bipartite at least twice independent dyeing, measure Mfi.Use FlowJo software (TreeStar) further to process the flow cytometry spectrum.Use XLFit4.0 (IDBS) and dose response one site model 205 to measure half maximum combined.

Surface plasma resonance

Use Biacore instrument (Biacore, GE-Healthcare, Uppsala), by the bonding properties of surface plasma resonance (SPR) technical Analysis unit price anti-IGF-IR antibodies.This system is Erecting and improving for studying interaction of molecules.Therefore it allows continuous Real Time Monitoring part/analyte combination, and is determined at association rate constant (ka), dissociation rate constant (kd) and the equilibrium constant (KD) of many measure in arranging.The SPR technology is based on the specific refractory power of measuring the coated bio-sensing chip near surface of gold.The lip-deep quality change that the variation of specific refractory power indication is caused by the interaction of the analyte that injects in fixing part and solution.If fixing part on the molecule mating surface mass penalty reduce in the next quality of the situation of dissociating.For catching, use amine coupling chemistry that anti-human IgG antibody is fixed on the surface of CM5 bio-sensing chip.With the 1:1 mixture activation flow cell of the flow velocitys of 5 μ l/ minutes with 0.1M N-hydroxy-succinamide and 0.1M3-(N, N-dimethylamino) propyl group-N-ethyl carbodiimide.At sodium-acetate, in pH5.0, inject the anti-human IgG antibody of 10 μ g/ml.Process in an identical manner with reference to the contrast flow cell, but only with the vehicle damping fluid, replace capture antibody.Injection 1M thanomin/HC1pH8.5 confining surface.Dilution IGF-1R antibody injection in HBS-P.All interactions are carried out under 25 ℃ (standard temperatures).After each is in conjunction with circulation, with 5 μ l/ minutes flow velocitys, inject 60 seconds 3M magnesium chloride regeneration solns to remove the protein of any non-covalent combination.Speed detection signal with 1 signal of per second.The sample that injection concentration increases.Figure 17 has described the mensuration form of application.The capture antibody density of the low loading density of selection and IGF-1R antibody are to force the unit price combination.

For affinity, measure, by using the anti-His antibody (Penta-His with surperficial coupling, Qiagen) catch the acceptor of His mark, people FcgIIIa is fixed on the CM-5 sensing chip, and described anti-His antibody is coupled on the surface of SPR instrument (Biacore T100) by standard amine coupling and sealing chemistry.After FcgRIIIa catches, at 25 ℃ of flow velocity injection 50nM IGF1R antibody with 5 μ L/ minutes.Use afterwards 10mM glycine-HC1,60 pulse per second (PPS) regeneration chips of pH2.0 solution.

The cytotoxic assay of antibody dependent cellular (ADCC)

Measure by the antibody-mediated effector function of anti-IGF-IR antibodies.For the antibody of measuring generation, cause the ability of immune effector mechanism, carried out cytotoxicity (ADCC) research of antibody dependent cellular.In order to study the effect of antibody in ADCC, in cell culture incubator under 37 ℃ with BATDA solution (Perkin Elmer) the mark DU145IGF-IR express cell (1x10 of 1 μ l/ml ⁶Individual cell/ml) 25 minutes.Afterwards, with 10ml RPMI-FM/PenStrep, wash 4 cells and with 200x g centrifugal 10 minutes.In the end before centrifugation step, measure cell count and from after the RPMI-FM/PenStrep substratum of precipitation in be diluted to 1x10e5 cell/ml.In the every hole of round bottom plate, place 5,000 cells of 50 μ l volumes.50 μ l cell suspension things are added in to final concentration scope in 50 μ l cell culture medium volumes at the HuMAb antibody of 25-0.1 μ g/ml.Afterwards, the E:T ratio with 25:1 adds 50 μ l effector cells, the PBMC of fresh separated.With the centrifugal plate of 200x g 1 minute, it is then the step of hatching 2 hours at 37 ℃.After hatching, with 200x g eccentric cell 10 minutes, results 20 μ l supernatants also were transferred to the Optiplate96-F plate.Add 200 μ l europium solution (Perkin Elmer, in room temperature) and on shaking table, hatched plate 15 minutes.Use the Eu-TDA scheme of Perkin Elmer, quantitative fluorescence in time-resolved fluorescent agent (Victor3, Perkin Elmer).The % that discharges with the maximum of the TDA fluorescence-enhancing agent in the target cell that passes through the washing agent cracking of the spontaneous release correction of the TDA to each target cell represents by the degree of the lysis of ADCC.

The IGF-1R internalization is measured

According to the combination of antibody of the present invention and antigen-binding proteins and IGF-1R, cause internalization and the degraded of acceptor.Can express HT29CRC cell and IGF-1R targeting antibodies by hatching IGF-1R, follow by ELISA quantitatively in cell lysate remaining IGF-1R protein level monitor this process.

For this purpose, under 37 ℃ and 5%CO2, in 96 hole MTP, has night incubation 1 in the RPMI of 10%FCS, 5x10 ⁴The HT29 cell of cells/well is to allow cell attachment.Morning, the 100 μ l anti-IGF-1 R antibodies that suck substratum and add concentration to dilute among RPMI+10%FCS from the dilution step with 1:3 of 10nM to 2pM.Cell and antibody were hatched 18 hours under 37 ℃.Afterwards, again remove substratum add 120 μ l MES lysis buffers (25mM MES pH6.5+ is complete).

For ELISA, in the coated polystyrene board (Nunc) of the mould antibiotin of 96 pore chain, add the MAK of (final concentration 2.4 μ g/m1) that 100 μ l dilute in 3%BSA/PBST with 1:200<hu IGF-1R α>hu-1a-IgG-Bi (Ch.10) and continuing to shake under incubated at room 1 hour.Remove afterwards the hole inclusion, every hole is washed three times with 200 μ l PBST.Every hole adds 100 μ l lysis solution, on oscillator plate, again incubated at room 1 hour, and washes three times with 200 μ l PBST.After removing supernatant, add the PAK that dilutes with 1:750 in 100 μ l/ holes<people IGF-1R α>Ra-C20-IgG (Santa Cruz#sc-713) in 3%BSA/PBST, then as above-mentioned carry out same hatch with washing room every.In order to detect the specific antibody in conjunction with IGF-1R, add the rabbit antibody (Cell Signaling#7074) of the polyclone horseradish peroxidase of diluting with 1:4000 in 100 μ l/ holes in 3%BSA/PBST.Again after 1 hour, by as above-mentioned abundant washing, again removing unconjugated antibody 6 times.For the quantitative antibody of combination, add 3 of 100 μ l/ holes, 3'-5,5'-tetramethyl benzidine (Roche, BM-Blue ID.-Nr.11484281) incubated at room 30 minutes.Finally by adding the 1M H2SO4 color development stopping reaction in 25 μ l/ holes, and in 450nm wavelength place measure light absorption.Use the cell of not using antibody treatment as 0% contrast of lowering, use lysis buffer to contrast as a setting.

The IGF-1R autophosphorylation is measured (IGF-1 stimulation)

IGF-1R antibody target IGF-1R causes suppressing the autophosphorylation that IGF-1 induces.We have studied the autophosphorylation inhibition that the unit price IGF-1R antibody of not tying hand-hole is compared parent IGF-1R IgG1 antibody.For this purpose, when the unit price that has different concns and divalence IGF-1R antibody, with the 10nM rhIGF-1, processing the mouse fibroblast cell of expressing people IGF-1R is 3T3-IGF-1R cell 10 minutes.After lysis, by the combination of phosphoric acid-IGF-1R specific ELISA and people IGF-1R specificity capture antibody and phosphoric acid-tyrosine-specific detection antibody, measure the level of the IGF-1R albumen of phosphorylation.

The mensuration of PK performance: the single dose kinetics in mouse

Method

Animal:

The NMRI mouse, female, raising is 23-32g in compound administration time point body weight.

Research approach:

Single intravenous injection dosage for 10mg/kg, be divided into 3 groups by mouse, every group of 2-3 animal.After administration 0.5,168 and 672 hour from organizing 1 blood sample collection, after administration 24 and 336 hours from organizing 2 blood sample collections, after administration 48 and 504 hours from organizing 3 blood sample collections.

By puncture after eyeball, obtain approximately 100 μ L blood samples.Room temperature after 1 hour by centrifugal (9300xg) 2.5 minutes from blood, obtaining at least 40 μ l serum samples.In centrifugal rear direct freezing serum sample refrigerated storage in-20 ℃ until analyze.

Analyze:

Use 1% mice serum, with enzyme-linked immunosorbent assay (ELISA), measure the concentration of people's antibody in mice serum.In the first step, make the biotinylated monoclonal antibody (mAb<hFc γ for people Fc γ _PAN>IgG-Bi) in conjunction with the coated titer plate of streptavidin.In next step, add respectively serum sample (with different extent of dilution) and reference standard thing and make itself and the mAb that fixes<hFc γ _PAN>IgG-Bi combination.Then add the digoxin monoclonal antibody (mAb<hFc γ for people Fc γ _PAN>IgG-Dig).By anti-Dig-horseradish peroxidase antibody conjugates, detect people's antibody.Use the substrate of ABTS solution as horseradish peroxidase.That uses does not make it possible to quantitative assay people antibody in the mice serum sample with the specificity of catching and detect antibody of mouse IgG cross reaction.

Calculate:

By non-compartment (non-compartmental) analytical calculation pharmacokinetic parameter, use pharmacokinetics appraisal procedure WinNonlin ^TM, version 5.2.1.

Table 1: the pharmacokinetic parameter of calculating:

Use following pharmacokinetic parameter evaluator antibody:

The starting point concentration (C0) that is used for the estimation of pill IV model.

Maximum concentration (the C that observes _max), at (T _max) time occurs.

Maximum time (the T that observes concentration _max).

Area A UC under concentration/time curve (0-inf), by from the time 0 to infinitely-great linear trapezoid method (use linear interpolation) calculating.

Apparent half life (the T of end eventually _1/2), from equation: T _L/2=ln2/ λ z.

CLTB (CL), calculate with dosage/AUC (0-inf).

Vdss (Vss), (MRT (0-inf) calculates, and is defined as AUMC (0-inf)/AUC (0-inf) with MRT (0-inf) x CL.

B. embodiment:

Embodiment 1:

The generation of univalent antibody

Based on the principle of design shown in Figure 1A, we have designed (SEQ ID NO:1 and SEQ ID NO:2 for c-Met; C-Met5D5MoAb (" wt ")), IGF-1R (SEQ ID NO:3 and SEQ ID NO:4.; IGFlR AKl8MoAb (" wt ")) and HER3 (SEQ ID NO:5 and SEQ ID NO:6; Her3205MoAb (" wt ")) monovalent antigen binding protein.In addition, (SEQ ID NO:7 and SEQ ID NO:8 for c-Met have been designed; C-Met5D5MoAb KiH), IGF-1R (SEQ ID NO:9 and SEQ ID NO:10; IGFlR AK18MoAb KiH) and HER3 (SEQ ID NO:11 and SEQ ID NO:12; Her3205MoAb KiH) identical univalent antibody, its CH3 partly mix sudden change with support by the knot hand-hole ( kNob- iNto- hOle) (, KiH) the allos dimerization of technology (Merchant, A.M. wait the people, Nat.Biotechno1.16 (1998) 677-681).As above-mentioned, all univalent antibodies of transient expression in the HEK293 cell, and subsequently by after the a-protein affinity chromatography, connecing the size exclusion purifying.

The tomographic map of the size exclusion chromatography of 3 kinds of different monovalent antigen binding proteins not tying hand-hole has been described in Fig. 3-5, and the corresponding SDS-PAGE under non-reduced and reductive condition.

By SEC-MALLS (Fig. 4 C), confirm the size at different peaks, and by mass spectrum, confirm the identity of the protein that separates.These data show that jointly the CHI-CL intersection allows the univalent antibody that easily purifying is pure (peak 3 in Fig. 3, the peak 2 in Fig. 4, the peak 3 in Fig. 5) and ties hand-hole to force to carry out the allos dimerization without in the Fc part, comprising.The divalence as byproduct before the monovalent antigen binding protein peak that this product can be by describing in size exclusion chromatography and Fig. 1 C, the antigen-binding proteins of dimerization form (, the MoAb dimer) and baseline separation.Crosslinked dimeric most of halfcystine bridges are not closed in divalence, dimerization construct, this causes observing the primary product of observing at the 100kDa place in SDS-PAGE under non-reduced condition, rather than (the peak 2 in Fig. 3 at the 200kDa place as expected, peak 1 in Fig. 4, the peak 2 in Fig. 5).The more aggregation of high molecular is described at the extra peak of observable c-Met5D5MoAb (" wt ") and Her3205MoAb (" wt ") (peak 1 in Fig. 3, the peak 1 in Fig. 5).These are different from the univalent antibody of describing in WO/2007/048037, wherein by conventional means, can not separate the univalent antibody mixture (Fig. 2) of allos dimerization and homologous dimerization.

The tomographic map of the size exclusion chromatography of 3 kinds of different monovalent antigen binding proteins with knot hand-hole has been described in Fig. 6-5, and the corresponding SDS-PAGE under non-reduced and reductive condition.

By applying this knot hand-hole technology for Fc allos dimerization, can improve allos dimerization monovalent antigen binding protein than the dimeric fractional yield of divalence MoAb, as shown in Fig. 6-8.

Embodiment 2:

C-Met phosphorylation (Fig. 9)

C-Met has been described to carcinogenic Tyrosylprotein kinase, and its imbalance promotes cell transformation.The antibody of target c-Met had been described in the past.MetMAb/OA-5D5 (Genentech) is one of the such antibody that suppresses the ligand dependent activation of c-Met.Because bivalent antibody activates, it is transformed into the single armed construct, wherein lacks a FAb arm, stays univalent antibody.In order to prove the similar effect of OA-5D5 and monovalent antigen binding protein c-Met MoAb (c-Met5D5MoAb (" wt ")), lacking or having unique known c-Met part, during HGF, hatch A549 cell and each antibody.Different from divalence MetMAb (MetMAb (biv.Ab)), none antibody has activating potential when lacking HGF.In addition, as expectedly, the receptor phosphorylation that c-Met MoAb (c-Met5D5MoAb (" wt ")) effective inhibition part the same as OA-5D5 induced.Non-specific human IgG control antibodies is on the not impact of HGF dependency c-Met receptor phosphorylation.

Embodiment 3:

Cell binding (Figure 10) with c-Met express cell system

On the A549 cell, proved the Cell binding of monovalent antigen binding protein c-Met MoAb (c-Met5D5MoAb (" wt ")).3 times of dilution series of the antibody of cell suspension thing and indication (100-0.0003 μ g/mL) are hatched.Use is in conjunction with the two anti-antibody that manifest combination of the Alexa488 coupling of human normal immunoglobulin constant region.On FACS Canto (BD Biosciences) flow cytometer, measure unicellular fluorescence intensity.In the combination of c-Met MoAb and OA-5D5, do not observe difference, prompting c-Met MoAb (c-Met5D5MoAb (" wt ")) is effectively in conjunction with cell surface c-Met.

Half maximum combined

OA-5D5： 1.45nM

c-Met MoAb 1.57nM

Embodiment 4:

IGF-1R binding affinity (Figure 11)

By surface plasma resonance (SPR), compared monovalent antigen binding protein IGF1R MoAb (IGF1R AK18MoAb (" wt ")) and parent<IGF-1R > combination of IgG1 antibody and IGF-1R ectodomain.Figure 17 has described the SPR that measures unit price avidity and has measured scheme.Analysis (2 mensuration) is presented in univalent antibody and has kept the IGF-1R binding affinity.

Embodiment 5:

Cell binding (Figure 12) with IGF-1R express cell system

On the A549 cell, proved the Cell binding of monovalent antigen binding protein IGF1R MoAb (IGF1R AK18MoAb (" wt ")).Use Accutase (Sigma) to separate the A549 cell that is in logarithmic phase, and use 2x10e5 cell hatching for each single antibody.The MoAb that adds three times of dilution series (100-0.0003 μ g/mL).Use manifests the antibody of combination in conjunction with two anti-(5 μ g/mL) of the Alexa488 coupling of human normal immunoglobulin constant region.With 7-AAD (BD), to dead cell stain and from analyze, get rid of.On FACS Canto (BD Biosciences) flow cytometer, measure unicellular fluorescence intensity.Data presentation is variant in half maximum combined with cell, this be because IGF-1R IgG1 antibody can be with two arms in conjunction with the IGF-1R on cell and show the avidity effect, and only available single armed combination of univalent antibody.

Half maximum combined

IGF-1R(150kDa)： 0.76nM

IGF-1R MoAb(100kDa)： 5.65nM

Embodiment 6:

ADCC induces (Figure 13)

Can use peripheral blood lymphocytes (PBMC) measurement of donor source to raise by the non-sugar transformation of cancer cells and the effector cell of the sugared antibody of transforming.The cell-mediated cytotoxicity of the cracking of cancer cells and NK is relevant and to raise the ability of NK cell proportional with antibody.In this arranges especially, when lacking and having each antibody, the DU145 prostate cancer cell is hatched with PBMC with the ratio (DU145:PBMC) of 1:25.After 2 hours, use BATDA/ europium systems measurement as above lysis.The % that discharges with the maximum of the TDA fluorescence-enhancing agent in the target cell that passes through the washing agent cracking of the spontaneous release correction of the TDA to each target cell represents by the degree of the lysis of ADCC.Data presentation, although the apparent avidity to the IGF-1R on cell is lower, the monovalent antigen binding protein IGF1R MoAb (IGF1R AK18MoAb (" wt ")) of non-sugar transformation induces ADCC better than the parent IGF-1R antibody of non-sugar transformation on high density.Surprising, the monovalent antigen binding protein IGF1R MoAb (IGF1R AK18MoAb (" wt ")) of non-sugar transformation even induces ADCC better than the parent IGF-1R antibody of sugar transformation on high density, described parent IGF-1R antibody shows and descends in ADCC measures when moving towards high density.Such unit price IGF-1R antigen-binding proteins (IGF1R AK18MoAb (" wt ")) therefore can represent the promising method of the IGF-1R on target cancer cell, the IGF-1R internalization that the mediation of described unit price IGF-1R antigen-binding proteins reduces and the ADCC (see below) that strengthens due to the internalization that reduces, and the amount that makes to take the Fc part of the FcRIIIa acceptor on the effector cell doubles; As the antibody of non-sugar transformation or the antibody of transforming as sugar.

Embodiment 7:

The IGF-1R internalization is measured (Figure 14)

The internalization that causes IGF-1R by divalence parent IGF-1R antibody target IGF-1R.We have studied the internalization performance of monovalent antigen binding protein IGF1R MoAb (IGF1R AK18MoAb (" wt ")).Data presentation in Figure 14, when monovalent antigen binding protein IGF1R MoAb (IGF1RAK18MoAb (" wt ")) was combined, the internalization of IGF-1R was being tired and is definitely all being reduced aspect internalization.

By the IGF-1R on divalence IGF-1R antibody target tumour cell, cause internalization and the lysosome degraded of IGF-1R.We have studied the internalization performance of monovalent antigen binding protein IGF1R MoAb (IGF1R AK18MoAb (" wt ")).For this reason, the monovalent antigen binding protein IGF1R MoAb (IGF1R AK18MoAb (" wt ")) of use different concns and divalence parent IGF-1R antibody treatment HT29 colon cancer cell are 18 hours.After lysis, by the IGF-1R specific ELISA, measure the residue level of IGF-1R albumen.

Figure in Figure 20 shows, when monovalent antigen binding protein IGF1R MoAb (IGF1R AK18MoAb (" wt ")) is combined, the internalization of IGF-1R tire and absolute internalization aspect all reduced.Maximum internalization is reduced to 48% (MoAb) from 83% (IgG1), and the half maximum desired concn that suppresses increases to 1.5nM (MoAb) from 0.027nM (IgG1).

Embodiment 8:

IGF-1R autophosphorylation (IGF-1 stimulation) (Figure 15)

By IGF-1R antibody target IGF-1R, cause the inhibition of the autophosphorylation that IGF-1 induces.We have studied the autophosphorylation that monovalent antigen binding protein IGF1R MoAb (IGF1R AK18MoAb (" wt ")) compares parent IGF-1R IgG1 antibody and have suppressed.For this purpose, when having the monovalent antigen binding protein IGF1R MoAb of different concns (IGF1R AK18MoAb (" wt ")) and divalence parent IGF-1R antibody, with the 10nM rhIGF-1, processing the mouse fibroblast cell of expressing people IGF-1R is 3T3-IGF-1R cell 10 minutes.After lysis, by combination people's IGF-1R specificity capture antibody and phosphoric acid-tyrosine-specific, detect the phosphoric acid of antibody-IGF-1R specific ELISA and measure the level of phosphorylation IGF-1R albumen.

Data presentation in Figure 15, monovalent antigen binding protein IGF1R MoAb (IGF1R AK18MoAb (" wt ")) can suppress the autophosphorylation that IGF-1 induces, although due to the unit price on cell in conjunction with the avidity effect of divalence combination (lack due to) at higher control of the concentration.The required concentration of half maximum inhibition increases to 27.9nM (MoAb) from 1.44nM (IgG1).Because it is slightly more not remarkable that the difference (19 times) of unit price IC50 value in the IGF-1R autophosphorylation with bivalent antibody is compared IGF-1R downward (59 times), can not only use the avidity on IGF-1R to reduce the impact of explanation unit price in conjunction with the reduction on lowering.

Embodiment 9:

The stability of IGF-1R monovalent antigen binding protein (Figure 16)

Stability by dynamic light scattering research monovalent antigen binding protein IGF1R MoAb as above (IGF1R AK18MoAb (" wt ")).Briefly, by the gathering tendency of the DLS time course experimental evaluation monovalent antigen binding protein IGF1R MoAb at 40 ℃.Through 5 day time, measurable increase (Figure 22) of hydrodynamic radius (Rh) (with reference to Figure 10) of the monomer fraction of separation can't be detected.

Embodiment 10:

The mensuration of PK performance

(in the method chapters and sections) measure the pharmacokinetic performance according to univalent antibody of the present invention in the NMRI mouse in single dose PK research as mentioned above, described NMRI mouse be female, raise, body weight is the mouse of 23-32g when the compound administration time point.

In following table, provide the PK performance, and prompting monovalent antigen binding protein IGF1R MoAb (IGF1R AK18MoAb (" wt ")) compares parent<IGF-1R > IgG1 antibody has improved PK performance.

Table 2:PK performance is summed up

		<IGF-1R>IgG1 antibody	<IGF1R>MoAb
				C0	μg／mL	81.9	298.32
Cmax	μg／mL	80.7	290.2
				Tmax	h	0.5	0.5
AUC0-inf	h＊μg／mL	9349	20159
				term t1／2	h	106.2	148.9
Cl	mL/min/kg	0.018	0.0083
				Vss	L／kg	0.16	0.082

Embodiment 11:

ESI-MS tests IGF-1R MoAb (Figure 17 and 18)

Transient expression also passes through a-protein chromatography and size exclusion chromatography purifying monovalent antigen binding protein IGF1R MoAb (IGF1R AK18MoAb (" wt ")).After preparation property SEC, be collected in the antibody of wash-out in 2 independent peaks (peak 1 and peak 2).The analytical SEC of fraction 2 (peak 2), corresponding to the molecular weight of 100kDa, points out the monomer of determining.SEC-MALS has verified initial SEC result, and shows that the Mw of fraction 2 (monomer) is 99.5kDa.The SDS-PAGE of this fraction under sex change and reductive condition analyzes a master tape that has shown the apparent molecular weight with 50-60kDa.Fraction 2 (monomer) has shown the master tape of about 100kDa MW under non-reduced condition.

Fraction 1=165mL

Fraction 2=190mL

ESI-MS spectrum from the de-glycosylation MoAb of fraction 2 shows a peak series corresponding to the monomer with 98151Da quality.

Table 3: sum up from the MS data that the non-reduced ESI-MS of fraction 2 measures.

Fraction	Molecular weight, monomer (theoretical value 98162Da)
		Fraction 2	98151Da

The MS of fraction 2 under reductive condition measures correct sequence and the expression that shows construct.From the MS data presentation of fraction 2 two different heavy chains with 47959Da and 50211Da molecular weight of about equivalent.

Table 4: sum up from the MS data that the reduction ESI-MS under the reductive condition of fraction 2 measures.

Embodiment 12:

The production of the antigen-binding proteins of sugar transformation

For the production of the antigen-binding proteins of sugar transformation, use calcium phosphate method with 4 kinds of plasmid transfection HEK-EBNA cells.The plasmid of 2 kinds of encoding antibody chains, a kind of be used to merging GnTIII expression of polypeptides (GnT-III expression vector), and a kind of for mannosidase II expression (golgi body mannosidase II expression vector), ratio is 4:4:1:1.In the T bottle, use to supplement the monolayer culture thing culturing cell of DMEM substratum to adhere to of 10%FCS, and when cell be 50-80% transfectional cell while converging.For the transfection of T150 bottle, first 24 hours of transfection, at 15,000,000 cells of 25ml DMEM inoculation of medium that supplemented FCS (10%V/V final concentration), and cell is placed in and has 5%CO ₂In the incubator of atmosphere, under 37 ℃, spend the night.For each, treat the T150 bottle of transfection, by mixing 94 μ g, be divided into total plasmid vector DNA of light and heavy chain expression carrier, water is to final volume 469 μ l, and 469 μ l1M CaCl ₂Solution prepares DNA, CaCl ₂Solution with water.This solution is added to 938 μ l50mM HEPES, and 280mM NaCl, 1.5mM pH are 7.05 Na ₂HPO ₄Solution, mixed 10 seconds and in room temperature standing 20 seconds immediately.With 10ml, supplemented the DMEM diluted suspension of 2%FCS and be added in T150, having replaced existing substratum.Then add other 13ml transfection media.At 37 ℃, 5%CO ₂Culturing cell approximately 17 to 20 hours, then use 25mlDMEM, and 10%FCS replaces substratum.After substratum exchange approximately 7 days by with centrifugal 15 minutes results conditioned mediums of 210xg, sterile filtration (0.22um filter) solution to add final concentration be the sodiumazide of 0.01%w/v, and be stored in 4 ℃.

Claims

1. monovalent antigen binding protein, it comprises

2. according to claim 1 monovalent antigen binding protein, described monovalent antigen binding protein is characterised in that

I) change the CH3 structural domain of a heavy chain,

With

Ii) change the CH3 structural domain of another heavy chain,

3. according to claim 2 monovalent antigen binding protein, described monovalent antigen binding protein is characterised in that

4. according to claim 3 monovalent antigen binding protein, described monovalent antigen binding protein is characterised in that

5. the monovalent antigen binding protein of according to claim 1 to 4, described monovalent antigen binding protein is characterised in that it is human IgG1's isotype.

6. according to claim 1 monovalent antigen binding protein, described monovalent antigen binding protein is characterised in that and comprises

B) modified heavy chain, it comprises the aminoacid sequence of SEQ ID NO:2; Or

B) modified heavy chain, it comprises the aminoacid sequence of SEQ ID NO:4; Or

B) modified heavy chain, it comprises the aminoacid sequence of SEQ ID NO:6; Or

B) modified heavy chain, it comprises the aminoacid sequence of SEQ ID NO:8; Or

B) modified heavy chain, it comprises the aminoacid sequence of SEQ ID NO:10; Or

B) modified heavy chain, it comprises the aminoacid sequence of SEQ ID NO:12.

7. 2,3,4 or 6 monovalent antigen binding protein according to claim 1,, described monovalent antigen binding protein is characterised in that a) and b) modified heavy chain be the IgG1 isotype, and antigen-binding proteins is afucosylated, has 80% or lower Fucose amount in oligosaccharides (sugar) total amount at the Asn297 place of human IgG1's isotype.

8. the pharmaceutical composition of the monovalent antigen binding protein of according to claim 1 to 7.

9. pharmaceutical composition, it comprises according to claim 1-7 monovalent antigen binding protein and at least a pharmaceutically useful vehicle.

10. the monovalent antigen binding protein of according to claim 1 to 7, it is used for the treatment of cancer.

11. the monovalent antigen binding protein of according to claim 1 to 7 is for the manufacture of the purposes of the medicine for the treatment of cancer.

12. treatment needs the patient's of therapy method, described method feature is the monovalent antigen binding protein to according to claim 1 to 7 of patient's administering therapeutic significant quantity.

13. prepare the method for the monovalent antigen binding protein of according to claim 1 to 7

Said method comprising the steps of

A) use the carrier transformed host cell, described carrier comprises the nucleic acid molecule of the monovalent antigen binding protein of coding according to claim 1 to 7,

The nucleic acid of the monovalent antigen binding protein of according to claim 1 to 7 14. encode.

15. comprise the carrier of nucleic acid according to claim 14.

16. comprise the host cell of carrier according to claim 15.